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MICAL is a large multi-domain monooxygenase with orthologues in flies and 
humans. MICAL is known to play an important role in axon guidance through 
semaphorin signaling and, in particular, it has recently been found to influence actin 
polymerization, with certain constructs capable of disassembling F-actin through 
methionine oxidation. MICAL also can produce hydrogen peroxide, a potential signaling 
molecule. In the following, I expressed and purified several proteins, including the 
MICAL-1 C-terminus, the cytoplasmic portion of the semaphorin receptor Plexin-A1, 
and the small GTP-binding protein Rnd1, combined these with MICAL constructs of 
varying length, and used kinetics, co-sedimentation, peroxide quantitation, HPLC, and 
size exclusion in an effort to characterize the factors necessary to activate MICAL's 
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Chapter 1: Introduction. 
 1.1 Introduction to neurodevelopment and axon guidance. 
 Nervous systems, ranging from those of invertebrates to those of humans, show a 
remarkable degree of organization and structural intricacy. Even with a comparatively 
rudimentary nervous system and a brain consisting of a mere few hundred thousand cells, 
a normal fruit fly exhibits distinct nerve tracts that interconnect central ganglia with the 
motor and sensory organs in highly specific and predictable ways (1,  2). In insects, these 
patterns first begin to appear within hours of embryonic development with the appearance 
of a rudimentary neural tube, and within 16-20 hours are established and clearly 
recognizable by distinctive patterns of axon bundling, de-fasciculation and growth at 
critical choice-points (3). 
 In the far more complex mammalian nervous system, this challenge of 
organization is all the more daunting: not thousands, but billions of neurons must grow, 
differentiate and, crucially, extend axonal and dendritic projections in the correct 
directions to form many trillions of precise synaptic connections with neighboring 
neurons, muscle cells, or glands. Even slight perturbations in this development from the 
norm can lead to severe or lethal phenotypes (4-7). 
 The seemingly spontaneous development of such structures naturally raises 
questions regarding their underlying mechanisms. Beginning with the closure of the 
neural tube, it is thought that a carefully orchestrated succession of gene expression 
events establishes morphogen gradient patterns of increasing complexity, and constitutes 
an implicit "program" of nervous system development (4). 
 This program has been gradually (but far from completely) elucidated in recent 
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years by the identification of a plethora of morphogens and guidance molecules which 
are expressed in a developmental- and location-specific way, and direct the formation of 
specific neurological structures and cell types. These molecules include such well-known 
neural-patterning factors as Shh, Wnt, bone morphogenetic protein (BMP), and 
neurotrophins (1,  8). However, the program is far from being understood in its full 
intricacy, with many seemingly simple questions left unanswered. Moreover, the exact 
intracellular systems that transduce and affect the signals conveyed by these 
developmental factors are still, in many cases, poorly understood.  
 Of the many aspects of neural structure and differentiation, one of the most vital 
and promising areas of study in this regard has been axonal guidance. The pattern of axon 
path-finding, beginning with early neurite outgrowth and differentiation and ending in 
eventual innervation of their targets, constitutes an implicit "wiring diagram" of the 
nervous system. Within the brain, distinct sub-classes of neurons must extend axonal 
projections from highly specific regions of the cortex to equally precise areas of the 
thalamus, pons, tectum, or cortex itself (9), while motor and sensory axons must often 
grow tens of thousands of cell lengths before innervating their intended targets, with 
some exceeding a meter in length and showing extensive ramification into hundreds of 
synapses at their ends (2,  9). 
 1.2 Growth cone dynamics, guidance cues and receptors. 
 It is now known that the feat of axon guidance owes largely to the establishment 
of gradients of both secreted and cell-surface cues, which are produced during neural 
development and also after nerve injury (10-12). These cues are detected, either by direct 
contact or over a range of hundreds of micrometers, by a highly specialized, dynamic and 
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motile structure at the tip of the elongating axon known as the growth cone.  
 First observed by Cajal (3,  13), the growth cone is roughly fan-shaped and 
extends finger-like projections into the surroundings, called filopodia. Filopodia contain 
primarily F-actin fibers, which exhibit retrograde transport under the action of non-
muscle myosin. In addition, in a process called "treadmilling” G-actin monomers 
assemble at the leading edge of the filopodia, travel proximally (i.e. back towards the 
base or "central domain" of the growth cone), and then are disassembled, releasing G-
actin monomers for fresh polymerization (1,  8,  14).  
 Around the bases of the filopodia, webbing-like regions consisting primarily of an 
F-actin meshwork (as opposed to unidirectional fibers) form the lamellipodia, a kind of 
scaffolding region around the base of the filopodia, which accommodates organelles and 
also shows highly dynamic actin behavior. Still more proximally, in the central domain, 
the actin meshwork gives way to a more rigid zone of microtubules (Fig. 1.1), which also 
provide the structural integrity of the main shaft of the axon along its length (2,  8).  
 Control of the rate of actin fiber motion by myosin, or of the rates of 
polymerization at the leading edge and depolymerization within the cone, as well as of 
rigidity and bundling of actin fibers, allows for modulation of the cone's growth behavior 
with remarkable precision. In particular, though the exact mechanisms are still not fully 
understood, they allow precise control of the direction of the cone's growth by guidance 
cue gradients in the surroundings by differential rates of actin polymerization or 
disassembly on alternate sides of the growth cone (1,  8,  13).  




Figure 1.1 Representative diagram of a growth cone. Note the central (C) domain, 
dominated by microtubles, and the peripheral (P) domain, where actin dynamics in 
filopodial and lammelipodial structures plays a central role instead–although some single 
microtubules still intrude. The region between these is sometimes called the transitional (T) 




been distinguished: the ephrins, the netrins, the slits, and the semaphorins, along with 
 numerous cell-adhesion proteins and morphogens that are known to act in a guidance 
role (1,  15). Each family, in turn, is associated with a complementary family of 
receptors: Eph, DCC/UNC5, Robo, and Plexin, respectively.  
 Although there is considerable diversity within each of these families--some being 
wholly secreted, others membrane-bound, and acting over a variety of distance scales--
there are structural motifs that are conserved and also a general tendency for each family 
to exert an attractive or repulsive influence on developing axons (1,  15,  16). For 
example, the netrins are frequently attractive cues, drawing axons to grow in the direction 
of increasing cue concentration, while the semaphorins are mostly repulsive, directing 
axon growth away from the location of secretion. In some cases the generally attractive 
or repulsive nature of a cue may be altered or even reversed by so-called modulatory cues, 
or by the type of receptor being expressed–as in the case of netrins, which in spinal cord 
development are attractive while axons grow towards the midline and then, due to 
expression of different receptor types, become repulsive after reaching or crossing the 
commissure. Furthermore, axon guidance receptors may be bi-directional, as in the case 
of the Ephs, able to both receive and send signals  (1,  3,  15,  16). 
 The semaphorins, a particularly large and well-studied family of cues, and 
distinguished by the presence of the "sema domain", a 500-residue, seven-bladed beta 
propeller structure, as well as several Ig-like repeats and PSI-domains. Their receptors, 
the plexins (17), are single-pass transmembrane proteins that feature an ectodomain 
consisting of a similar arrangement and composition of subdomains to that of semaphorin  
(1,  6,  18). It is thought that the sema domains are naturally inclined to dimerize in an 
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edge-to-edge manner, giving a plausible mechanism of ligand recognition and receptor 
activation (15,  19-21).  
 There are about 20 semaphorin types in higher vertebrates, distributed in five 
numbered classes (3-7; 1 & 2 in invertebrates only), and nine plexins, with four classes. 
Perhaps the most abundant and best-studied of the subgroups is the Type 3 semaphorins, 
especially soluble Sema3A, the first semaphorin discovered; these are secreted by 
guidance substrates--such as glia, cells of the midline, and other axons--and bind to 
Plexin A receptors (particularly Plexin A1). Sema3A's interaction with Plexin A requires 
a co-receptor, Neuropilin-1 or -2, though other plexins can transduce semaphorin 
guidance signals by themselves, for example Sema4D with Plexin B1 (22,  23). 
 The plexin intracellular domain has an unusual structure, consisting of four main 
elements: a C1 domain, a rho-binding domain (RBD), a C2 domain, and an N-terminal 
helix. From both sequence analysis and the crystal structures of both plexin A3 and B1, it 
is apparent that the C1 and C2 domains rest together in a somewhat intertwined 
conformation and constitute a Ras-GTPase activating protein (Ras-GAP). As is typical of 
GAPs, that of plexin is marked by two conserved catalytic arginines (24-26). Plexin is 
unusual in the intercalation of the RBD between its two GAP domains, and among 
guidance receptors in directly interacting with small GTPases (26,  27). The RBD is 
capable of binding such Rho GTP-binding proteins as RhoD, Rac1, and Rnd1, with 
accompanying large variations in GAP activity--ranging from inhibition to strong 
activation, as assessed by cell contraction assays (28-31). 
 Though the exact mechanisms of plexin signal transduction remain unknown and 
are no doubt complex, they are thought to exist at rest in an autoinhibited conformation 
 
7 
for which the ectodomain plays a key role (32). Two main upstream requirements have 
been proposed for their full activation, while at least three main downstream effector 
pathways are recognized. The upstream requirements have been described as logically 
"AND-gate like" in that they must be simultaneously realized in order for full signaling to 
take place (20,  25,  29,  33). In the first place, receptor clustering must be induced (or 
halted, depending on the account), by semaphorin binding at the extracellular domain; in 
the second place, a suitable Rho protein in a GTP-bound state must interact with the 
plexin RBD (30,  34,  35).  
 Following activation of plexin, the guidance signal is thought to be relayed by 
three possible pathways:  
 1) activation of the plexin Ras-GAP, leading to effects on such diverse functions 
as PTEN activity (36), phosphorylation of cofilin by LIMK1 (14,  37), GSK-3 activation 
(38), and integrin adhesion (18,  25,  33);  
 2) binding of collapsin-response mediator proteins (CRMPs), which may 
subsequently be modified by phosphorylation or oxidation in order to influence GSK-3β 
activity or microtubule disassembly (27,  39,  40); or  
 3) activation of MICAL (Molecule Interacting with CasL) leading to direct 
chemical modification and disassembly of F-actin and hence, growth cone collapse or 
steering. 
 
 1.3 MICALs. 
 MICAL was discovered initially in lysates of COS-7 cells as an interaction 
partner of both CasL, a large multifunctional scaffolding protein involved in actin 
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bundling (and from which the name MICAL derives: Molecule Interacting with CAsL), 
and vimentin, a protein abundant in intermediate filaments (41). Further, MICAL was 
determined to interact through the SH3 domain of CasL, via a PPKPP motif near its C-
terminus, and mutation of the lysine of this motif was sufficient to abolish interaction. 
Association with vimentin also appeared to depend on the C-terminus of MICAL, though 
other regions of MICAL, notably its CH domain could also interact with CasL in 
isolation (41). 
 MICAL is a 118 kDa, 1048 residue protein found in a wide range of species 
including flies, mice and humans. There is one isoform in Drosophila and three in mice 
and humans (42). MICAL displays a distinct and diverse combination of conserved 
domains, linked by stretches of much more variable sequence (Fig. 1.2). In order from the 
N-terminus, these include a flavin-binding monooxygenase domain (MO; a.a. 1-484), the 
only known enzymatically active component of the protein; a calponin homology domain 
(CH; a.a. 516-617); a LIM domain (a.a. 690-752); a proline-rich region which includes 
the PPKPP motif (a.a. 822-827); a glutamate-rich region (a.a. 856-876); and finally, a C-
terminal domain (CTD) containing a predicted coiled-coil structure with an Ezrin-
Moesin-Radixin (ERM)-like sequence (a.a. 876-1048,  5,  40).  
 Of these, the most intensely studied regions of MICAL so far have been the MO 
and CTD. In a series of groundbreaking experiments shortly following the discovery of 
MICAL as an interaction partner of CasL, Kolodkin et al. (5) independently identified 
MICAL in a yeast two-hybrid screen and confirmed it by co-immunoprecipitation as a 
binding partner of the plexin A C2 domain in Drosophila. Furthermore, genetic 




igure 1.2a, domain diagram of MICAL-1 protein. MICALMO is the enzymatically active 
monooxygenase domain; CH is a single calponin-homology domain; LIM is a single zinc-
finger LIM motif; PPKPP is the proline-rich region that binds to CasL SH3 domain; Poly(E) 
is a polyglutamate repeat of uncertain function; and MICALCTD is the predicted coiled-coil 
domain that interacts with plexin intracellular C2 domain. 
 
Figure 1.2b. Structure of the monooxygenase domain of MICAL-1. Note the extensive 
open space surrounding the FAD, which is thought potentially capable of 




for proper axon guidance in flies and for response to Sema3A in cell cultures, with 
knockouts showing adult lethality and serious nerve de-fasciculation deficits similar to 
plexin knockouts. MICAL overexpression, conversely, produced excessive de-
fasciculation similar to that seen in plexin overexpression (5).  
 In the same work, MICAL's likely status as a flavin-monooxygenase also is 
implicated on several lines of evidence. First, sequence analysis revealed a GxGxxG 
motif characteristic of the dinucleotide-binding regions of flavoprotein monooxygenases, 
and mutagenesis of this to WxWxxW abolished guidance function (5). Second, purified 
MICAL proteins exhibited a yellowish color and an absorption peak at 425 nm 
characteristic of flavoenzymes. Third, the known monooxygenase inhibitor EGCG 
abrogated axon repulsion by Sema3A in a manner highly similar to MICAL knockout (5). 
However, it is worth noting that EGCG was subsequently found to cause human fl-
MICAL to precipitate, so this "inhibition" may actually be due to non-specific damage to 
the enzyme (43,  44). 
 X-ray crystallography and kinetics data have since given insight into the structure 
and catalytic activity of the MICAL MO domain and decisively confirmed its status as a 
flavoenzyme (42,  46). The structures of the other domains have been resolved only by 
NMR (CH and LIM), (45) or not at all (proline-rich and CTD). The MO domain shows 
only distant sequence similarity but large structural resemblance to two other families of 
flavoproteins, the aromatic hydroxylases and amine oxidases, although the binding 
pocket containing the flavin is considerably larger than these, suggesting an unusually 
large substrate, possibly a protein side chain (40,  42,  46).  
 Kinetics data shows that MICAL-MO consumes NADPH with a 10-times larger 
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rate for a given concentration than NADH. Product inhibition by NADP+ is also observed 
(42). Interestingly, the MO is capable of directly reducing O2 at a high rate (possibly as 
high as 77s-1,  42) to generate H2O2, sometimes described as a "NADPH oxidase" reaction 
(43,  44,  47), (Fig. 1.3). This reaction is of uncertain significance but hypothesized to 
play a role in signaling.  
 While hydrogen peroxide is normally thought of as a dangerous reactive oxygen 
species like superoxide and hydroxyl radical, recent studies (48-50) have indicated that 
the picture is considerably more complex, with the classic toxic effects of oxidative stress 
associated with H2O2 only appearing at a level well above that necessary for redox 
signaling. Studies in COS-7 cell lysates have shown strong H2O2 production in the 
presence of constitutively active MICAL constructs (40). 
 Aside from its interaction with vimentin, the significance of the MICAL CTD was 
first appreciated as the area of the protein responsible for its interaction with plexin, it 
being sufficient for the observed co-IP with Plexin C2 domain (5). Further investigation 
has produced strong evidence that the CTD functions in a dominant-negative, and likely 
auto-inhibitory fashion. For example, expression of a myristoylated (membrane-targeted) 
form of the protein was sufficient to create axon guidance phenotypes similar to MICAL 
knockout (5), and in COS-7 lysates the expression of a similar construct containing 
residues 761-1048 was able to abolish Sema3A-induced contraction (40). 
 Further work in Drosophila bristles has shown that the plexin-interacting (CTD) 
region, and for that matter the entire sequence of MICAL excluding the MO domain, is 
sufficient to cause changes in actin polymerization behavior consistent with a dominant-
negative (51). Conversely, deletion of the CTD produces constitutively active MICAL  
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Figure 1.3 Proposed mechanism of the MICAL NADPH-oxidase reaction. NADPH is 
used to convert FAD to FADH2, which then reacts with dioxygen. In most 
monooxygenases the resulting C4a-hydroperoxide is protected from bulk solvent but in 
MICAL it is vulnerable under certain circumstances, decomposing to H2O2. It is thought 
that in the presence of the appropriate protein substrate this reaction is averted, in favor 




constructs as measured by H2O2 production, cell contraction, axon guidance behavior,  
and bristle morphology (40,  51,  52). CTD deletion also leads to a decrease in the 
number of cells exhibiting actin stress fibers, as does mutation of key alanines to prolines 
to disrupt the CTD's coiled-coil structure (53).  
 In turn, rescue of these constitutively active, overexpression-like phenotypes is 
possible by co-expression or direct addition of the pure CTD region; for example, H2O2 
production in cell lysates is restored to normal levels (40). Finally, overexpression of the 
full-length form of MICAL (fl-MICAL)--that is, with a functional MO domain but the 
CTD attached and intact--generally results in limited or no phenotypic change, further 
suggesting that the natural state of the protein is autoinhibited (5,  53). In vitro, fl-MICAL 
in lysates and as purified protein is found to consume NADPH at a far slower rate than 
any constructs that omit the C-terminal region (40,  54). 
 The CTD is notably absent in the mammalian MICAL-2 isoforms, which unlike 
the other two, appears to be primarily nuclear in localization and function and is 
constitutively active (53,  55). Hence it must be regulated by some other mechanism. 
However, chimeric proteins combining the C-terminus of MICAL-1 with the MO- and 
CH domains of C2 show a reconstitution of the autoinhibited state seen in MICAL-1 and 
-3 (53).  
 Altogether, these results suggest that fl-MICAL exists in an autoinhibited state 
under normal conditions in the absence of semaphorin signaling. It appears plausible then, 
given the known concomitant roles of the CTD as auto-inhibitory domain and as the 
plexin-interacting region, that activation of plexin, presumably in the AND-gate like 
fashion described above, makes available binding regions on the plexin C2 intracellular 
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region which then competes the CTD away from the MO, allowing full MICAL activity 
to mediate growth cone collapse (56). 
 The role of the other components of the MICAL molecule remains obscure. For 
instance, although the typical role of CH domains is actin-binding, this typically happens 
in pairs of cooperating CH domains. The single MICAL CH domain, on the other hand, 
appears to add no actin-binding capacity; the MO domain alone binds actin as well as 
MICALMO-CH (44). Hence, its importance has only recently begun to be understood to 
play a necessary role for correct localization of MICAL to the region of growth cones, 
effective rescue of actin dynamics in fruit fly bristles and possibly axon guidance (51) as 
well as for binding of CRMP proteins (40). As for the other domains of MICAL, the LIM 
domain contains only a single zinc-finger and its function remains mostly unclear (44), 
while the glutamate-rich region, being very short, seems not to have any vital function, 
though it may conceivably provide electrostatic interactions with certain basic patches 
elsewhere on the MICAL molecule.  
 1.3.1 Mechanism of action of MICAL. 
 Regardless of the question of autoinhibition or the regulatory and binding 
functions of the various subunits (in which the CTD appears to play a special part), the 
exact chemical mechanism of MICAL monooxygenase activity in semaphorin signaling 
and growth cone collapse is still somewhat debated, although recent experiments have 
clarified new possibilities. It was proposed early on that MICAL may function entirely 
through production of H2O2 as a signaling molecule (42).  
 However, many facts also suggest that MICAL's physiological function may 
include, or even be limited to, direct chemical modification of a specific target molecule, 
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very possibly a protein side chain: the size of the active pocket, the potential toxicity of 
free H2O2 production at the level observed (at least for the non-autoinhibited enzyme), the 
areas of positively charged residues surrounding the entrance to the active pocket 
suggestive of a binding, as well as the fact that the known flavoenzymes most structurally 
similar to MICAL (aromatic hydroxylases and amine oxidases) produce H2O2 only as an 
adventitious leakage in the absence of substrate site (44,  42,  46), all support such a 
possibility. This has led to a search for potential substrates, although a small-molecule 
search among a number of amino acids, aromatic compounds and polyamines turned up 
no candidates, with many acting as inhibitors (43,  44).  
 In general, the distinction between direct substrate modification and modification 
by the presumably extremely high local peroxide concentrations generated close to the 
enzyme has been difficult to settle definitively. Although the most recent evidence 
weighs on the side of direct substrate modification, H2O2 signaling cannot be excluded 
(40,  44,  57). 
 In cell lysates, co-IP experiments show that semaphorin signaling induces CRMP 
binding to MICAL via the MO and LIM regions, and that co-expression of these two 
creates increased cell contraction reminiscent of semaphorin signaling (40). However, 
Amplex Red measurements revealed in this case that the addition of CRMP leads to a 
dramatic reduction of H2O2 production by normally constitutively active MICAL, feeding 
the surmise that CRMP is a direct substrate (44). 
 Other studies with CRMP have shown that this protein may be modified by 
MICAL through oxidation at Cys504, leading to the formation of a disulfide-linked dimer 
(58). This dimerization may be essential to downstream control of actin dynamics, as 
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mutations in either Cys504 of CRMP or Cys32 of THX (which exchanges with CRMP to 
reduce it back to the monomeric state) showed abrogation of normal Sema3A response 
(58).  
 These same studies also detected, using HyPer, an oxidation-sensitive GFP-based 
fluorophore, a rapid time-dependent increase in H2O2 production near the membrane 
following Sema3A stimulation that, along with the majority of cell contraction, is 
dispelled by knockdown of either MICAL-1 or -3 with siRNA (58). Immunoprecipitation 
also showed the appearance of the CRMP dimer within minutes following Sema3A 
stimulation, but only in the presence of active MICAL. Thus, the possibility that 
MICAL's H2O2-producing capacity is an essential part of semaphorin-plexin signaling 
remains very much an open one (58).  
 Perhaps the most critical and widely discussed advance in the search for a 
MICAL substrate came from a series of biophysical observations published in 2010-11 
(51):  
 Firstly, it was found through in-vitro co-sedimentation that MICAL has actin-
binding properties, which could assist in its modification of F-actin dynamics. For 
example, this raises the possibility of regulation of the actin-binding property by axon 
guidance signaling, possibly through the CTD displacement mechanism proposed earlier. 
MICAL monooxygenase could then, due to its extreme proximity to actin, either oxidize 
it through H2O2 production or direct modification of a side chain.  
 Secondly, when measured by NADPH consumption, it was found that in the 
presence of F-actin, constitutively active MICAL constructs (specifically, MICALMO-CH) 
exhibit a >100-fold increase in rate and in kcat/Km, further increasing the likelihood of F-
 
17 
actin being a direct substrate of MICAL (43,  59). This acceleration strongly supports the 
suspicion that F-actin is the physiological substrate of MICAL--although it may still be 
due to a conformational change upon actin-binding, for example, that places the flavin 
ring in a more exposed position for its reaction with O2.  
 Thirdly, these same MICAL constructs are capable of disassembling F-actin, and 
oppose the polymerization of G-actin. In co-sedimentation experiments, G-actin was 
stably polymerized, then combined with NADPH or both NADPH and MICALMO-CH. 
Ultracentrifugation to pellet F-actin revealed that while MICALMO-CH alone, or NADPH 
alone or with BSA control did not affect actin's polymerization state, NADPH with 
MICALMO-CH converted most, though notably not all, F-actin into G-actin (or, according 
to electron microscopy, fibers sufficiently small to elude ultracentrifugation). In addition, 
pyrene-actin timecourses also show dramatic effects on actin polymerization state by 
NADPH with MICALMO-CH, whether the MICAL is added at the beginning of, or well 
after the G-actin has had a chance to polymerize (59). 
 That the disassembly reaction does not go to completion, leaving residual F-actin 
even with large excesses of NADPH and long after addition of MICAL, remains 
somewhat of a puzzle, though one of disputed significance. Aggravating the issue is the 
fact that MICAL does not show distinct two-phase behavior with regard to the NADPH 
consumption rate that would be expected if an extremely fast actin-modifying reaction 
took place first, giving way to a far slower NADPH oxidase reaction; instead, the reaction 
rate remains moderately high throughout. Some groups (43,  44) claim this as evidence of 
"substrate recycling" whereby an equilibrium is achieved between MICAL modification, 
disassembly and actin re-polymerization; other data implies that a chemically permanent 
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modification is at work in the disassembly process by MICAL, meaning there is no 
measurable equilibrium. 
 In concert with these biophysical findings, genetic work in Drosophila bristles 
(which in fly morphogenesis are initially patterned upon processes of F-actin governed by 
Semaphorin/plexin signaling in a manner reminiscent of axonal guidance) showed 
dramatic defects in actin patterning upon overexpression, constitutive activity, or 
knockout of MICAL (51,  52). In the absence of MICAL signaling, the actin fibers 
appeared overly thick and rigid, and therefore formed abrupt ruptures instead of 
following the normal curvature of a wild-type bristle. Excessive signaling on the other 
hand converted the bundled and linearly oriented wild-type actin structure into a 
fragmented meshwork, with many points and branches, consistent with MICAL 
disrupting the actin polymerization more thoroughly (51). Confirming the link with 
semaphorin signaling, similar phenotypes appear when plexin mutations are introduced. 
The CH and MO domains appear to be essential to proper bristle formation, while as in 
earlier work the CTD acted in a dominant-negative fashion and constructs lacking it were 
constitutively active (51,  53). 
 Additional results from mass spectroscopy accompanying these discoveries aimed 
to determine the exact actin modifications involved in MICAL treatment, and the 
possible mechanism of their reversal. MICALMO-CH-treated actin was found to be 
consistently heavier by 32 daltons, consistent with the addition of two oxygens; these 
modifications localize to two methionine residues in the D-loop of the actin molecule, 
M44 and M47 (M46 and M49 in mammalian actin)  (55,  59,  60). To further investigate 
these modifications, mutations of either or both methionines to leucine were made and 
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their behavior after MICAL treatment was examined. Strikingly, mutations involving 
M44L all produce MICAL-resistant actin, which does not disassemble or show reduced 
polymerization when treated with MICALMO-CH (though no control was reported with 
H2O2)  (59).  
 Intriguingly, modification of M47 appears to have no effect whatsoever on F-actin 
susceptibility to MICAL; its role therefore remains unclear. How to square the fact that 
MICAL shows quantitative modification of two distinct residues--of which only one 
appears necessary for MICAL actin disassembly--with claims that MICAL is a "specific" 
modifier of actin is somewhat uncertain, and has yet to be thoroughly discussed or 
investigated. Hence, it is generally considered that the modification of M47 is simply a 
by-product of the modification of M44, due simply to its relative proximity on the D-loop 
region, especially given that the M47L actin mutant shows no resistance to MICAL-
based disassembly (59). 
 1.3.2. Unresolved questions in MICAL function. 
 How to square sulfoxidation, a stable chemical modification that does not 
spontaneously reverse itself under the conditions of the cell--and particularly not at a rate 
remotely commensurate with which the forward reaction is carried out by MICAL--with 
the apparent substrate recycling and lack of two-phase kinetics other groups have 
observed is one puzzle of MICAL's mechanism of action on actin dynamics that remains 
to be untangled.  
 An equally pressing question, given that this particular kind of stable modification 
has been observed and its effects are by this point well documented--M44L cells show a 
bristle phenotype similar to MICAL-/-, while yeast containing M44C were non-viable (44,  
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59)--is whether actin modified by methionine oxidation by MICAL is permanently 
modified and simply degraded or regenerated in some way--and if so, how. 
 Insight into this has come from experiments published by two groups, which both 
found that the selenoenzyme MsrB, a methionine sulfoxide reductase, is capable of 
restoring the polymerizability of MICAL-treated actin, and argue for its role as the 
physiological regulator of MICAL-based F-actin disassembly (52,  60). In this work, 
mass spectroscopy of actin treated first with MICAL and then MsrB shows the loss of the 
32 Da originally found to be added by MICAL, indicating that MsrB is indeed reducing 
methionine sulfoxide at both Met44 and Met47.  
 Importantly, given that MsrB is exclusively stereospecific to the R enantiomer of 
methionine sulfoxide--MsrA acts only on the S form--the finding that MsrB can 
completely reverse the disassembly and modification of actin by MICAL shows that 
MICAL, in addition to being markedly accelerated in the presence of F-actin, also 
modifies it stereospecifically. Together these add support to the idea that F-actin is a 
direct substrate of MICAL rather than being modified by locally high H2O2 
concentrations. However, there are conflicting reports on whether actin treated with H2O2, 
which is achiral and hence should show no inherent preference for pro-R or pro-S 
oxidation of methionine, shows partially (60) or negligibly (52) restored polymerization 
upon MsrB treatment. 
 In vivo, expression of MsrB appears necessary for a normal bristle phenotype and 
for correct nerve fasciculation in Drosophila, with MsrB deletion producing phenotypes 
reminiscent of MICAL- or plexin- overexpression. MsrB overexpression, on the other 
hand, appears capable of rescuing signs of MICAL overexpression (52), though the 
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reports disagree somewhat on the effects of MsrB overexpression; one observes clear 
changes in bristle phenotype and muscle organization similar to MICAL deletion (52), 
while the other finds no change in F-actin polymerization in HeLa cells (60).  
 Such evidence, on balance, appears to lay out an important regulatory role for 
MsrB in axon guidance and actin remodeling as a purposeful antagonist of F-actin 
disassembly by MICAL. On the other hand, a relatively small number of proteins are 
currently thought to be regulated by methionine oxidation (61,  62); possibly the most 
well known of them is CamKII. Moreover, recent mouse models have shown that 
simultaneous double knock-out of both MsrA and MsrB is wholly viable and produce 
minimal phenotypic abnormalities, mostly involving dietary requirements for methionine; 
no neurological or axon guidance issues were reported (61).  
 This raises doubts about the true necessity of MsrB as a regulator of actin 
oxidation state and function and possibly, by extension, re-intensifies questions as to the 
true role of MICAL in mammalian systems. Therefore, despite impressive and suggestive 
results on some fronts, the status and importance of MICAL in actin dynamics and 
particularly axon guidance remains to a large degree unresolved. 
 As well, the status of MICAL as a physiologically important actin modifier 
depends not on the behavior of MICALMO-CH, which is constitutively active, but on the 
full-length form, fl-MICAL, which is thought to be modulated by semaphorin/plexin 
signaling in a complex and sensitive way. Although it has been shown that deletion of fl-
MICAL can phenocopy that of plexin, evidence that overexpression of fl-MICAL 
produces strong phenotypes is contradictory at best. In the work of references (51) and 
(52), the expression of an additional copy of fl-MICAL seemed to produce noticeable 
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abnormalities, while in references  (40),  (53) and (60) it either did not or the effect was 
modest. Further, the original findings on MICAL linking it to plexin signaling showed 
ambiguity in the abundance of overexpression phenotypes of fl-MICAL and even in the 
phenotypic difference between knockout and overexpression: while “a large fraction of 
these MICAL GOF motor axon guidance phenotypes are consistent with increased 
defasciculation”, Kolodkin et al. admit that "GOF defects in some cases are quite similar 
to the defects we observe in MICAL mutants and defects reported in PlexA GOF 
mutants" (5). 
 There is also a general lack of kinetic and in vitro studies of the behavior of fl-
MICAL. What data there is suggest dramatic differences between MICAL orthologues 
across species, with human MICALMO-CH, for instance, proving much more active than the 
Drosophila orthologue (44).  
 Therefore, an investigation of the behavior of the full-length MICAL protein, 
particularly towards F-actin, and with comparison to the behavior of MICALMO-CH, is a 
necessary step in establishing its mechanism of action and activation. In addition to this, 
the hypothesis of how fl-MICAL is activated--with an AND-gate like mechanism 
involving plexin dimerization, GTP-bound Rnd1 binding, remains unconfirmed in vitro. 
In the following experiments, using purified proteins in vitro, several aspects of MICAL 
activity were examined: its actin-binding, actin-disassembling, and rate acceleration in 
the presence of F-actin, as well as its reaction to added plexin and Rnd1. 
  In general, I find that in contrast to the MICALMO-CH used in most published 
experiments thus far, fl-MICAL does not display the expected disassembly activity in the 
presence of F-actin. This much is consistent with the theory of autoinhibition, except that 
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the presence of F-actin does produce a sizable increase in NADPH consumption with no 
decrease in relative H2O2 production, suggesting that actin alone is sufficient to lift 
autoinhibition of the monooxygenase domain to a significant degree. 
 The plexin-Rnd1 results also, while partly supporting the existing theory, 
introduce ambiguity. In accord with the AND-gate model, these two factors are found 
capable of stimulating fl-MICAL monooxygenase activity, but they differ from the model 
in that they only appear to work in the absence of F-actin. It is possible that some specific 
factor other than these, as yet unidentified, is necessary for activation of F-actin 
disassembly by fl-MICAL. 
 There is also some evidence that the CTD, in purified form, is able to displace 
MICALMO and MICALMO-CH from F-actin fibers, lending support to the autoinhibitory 
model. However, under some conditions of experiment these results show a weak effect, 
that might not account for the degree of activity and enzymatic control needed for 





Chapter 2: Initial Cloning, Expression and Purification.  
 2.1 Introduction. 
 The process of reconstituting the hypothesized systems of MICAL function in 
vitro required acquiring the DNA for the genes, then successful expression of protein, 
and purification of the following proteins: MICALMO, MICALMO-CH, and fl-MICAL; 
CRMP; the intracellular domain of Plexin A1; mouse Rnd1; and a construct of the 
MICAL C-terminal region, called MICALCTD.  
 Techniques used in the cloning stage typically included PCR with Pfu polymerase, 
restriction digestion, clonase reaction and TOPO cloning. Clonase is a technique devised 
by Invitrogen to allow efficient, frame-conserving integration and removal of gene inserts 
into a variety of plasmids known as "donor vectors", using recombination between attP 
sites. TOPO cloning is a method that uses the topoisomerase activity of Taq polymerase 
to rapidly integrate the insert in the position of the 3' thymidine in the target sequence 5'-
(C/T)CCTT-3' in a rapid (5 min), ligation-free reaction.  
 For expression, standard BL21 cell lines were rendered competent by re-
suspending the cells on ice in 10 mM PIPES, 55 mM MnCl2, 15 mM CaCl2, and 250 mM 
KCl, and 10 mM MgSO4, pH 6.8, spinning and re-suspending once more, adding DMSO 
to a final concentration of 7%, and quick-freezing in liquid nitrogen.  
 2.2 MICAL-2 Cloning 
 PCR amplification of mouse MICAL-2 was attempted, using MICAL-2 cDNA. 
AccuPrime Pfx polymerase and SuperMix were used. Primers, dissolved to 100 nM, were 
of the following: for forward, without stop codon (NS); forward, with stop codon (S), and 
the reverse primer (Table 1). Reactions produced 350-550 ng/µL of DNA according to  
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Primer name Sequence Use 
PlexA1ic (α_), BamHI 
 
5’-CCG AAT GGA TCC ATG GAC AAC 
CTG GAG TCA CGG GTG-3’ 
Sense primer for all plexin-A1 
constructs containing C1 domain  
PlexA1ic (_ω), SalI 5’-CCG ATA GTC GAC TCA GCT GCT 
CAG GGC CAT TGT-3’ 
Antisense primer for all plexin-
A1 constructs containing C2 
domain 
PlexA1ic (A_), NheI 5’-CCG ATA GCT AGC ATG CAG CAG 
ATT GAC TAC AAG-3’ 
Sense primer for plexin-A1 RBD 
subclone 
PlexA1ic (_B), SacI 5’-CCG ATA GAG CTC TCA CTT GCT 
GCC ACG GTC GCC-3’ 
Antisense primer for plexin-A1 
RBD and C1-RBD subclone 
PlexA1ic (B_), BamHI 5’-CCG ATA GGA TCC CCG GCA GCA 
AGA TGG TCT CT-3’ 
Sense primer for plexin-A1 C2 
domain subclone 
mMICALopt (A_), BamHI 5’-TTA CGA GGA TCC GAA GCG ATC 
GAA AAA-3’ 
Sense primer for subcloning of 
MICALCTD 
mMICALopt (A’_), BamHI 5’-TAT GCC GGA TCC TCT AAC ATG 
CAG CCG-3’ 
Sense primer for subcloning of 
MICALPPPCTD 
mMICALopt (A”_), BamHI 5’-TTA CGA GGA TCC CCG CTG CCG 
CCG CTG-3’ 
Sense primer for subcloning of 
MICALCTD lacking  
mMICALopt (_B), SalI 5’-TAT CGT GTC GAC TTA CGC CGG 
CAT TTC ACG-3’ 
Antisense primer for subcloning 
of original MICALCTD construct 
mMICALopt (_B’), SalI 5’-TAT CGT GTC GAC TTA CAG TGC 
ATC GCG CTG-3’ 
Antisense primer for subcloning 
of pre-truncated CTD (CTD24) 
Mical1CTD(PP_) 5’-CTG AAT GAA ATC GAA CCG CCG 
ATG CGC GAA CTG GAA-3’ 
Forward mutagenic primer for 
disruption of CTD coiled-coil 
Mical1CTD(_PP) 5’-TTC CAG TTC GCG CAT CGG CGG 
TTC GAT TTC ATT CAG-3’ 
Reverese mutagenic primer for 
disruption of CTD coiled-coil 
mRnd1opt (a_), BamHI 5’-ATA CTA GGA TCC CGT GCA CCG 
CAA CCG-3’ 
Sense primer for amplification 
of mRnd1 
mRnd1opt (_b), SalI 5’-ATA GAT GTC GAC TTA GAC CGG 
AGA TTT CGG-3’ 
Antisense primer for 
amplification of mRnd1 




A260 measurement, and were purified using a QIAquick PCR purification kit. However, 
very little DNA eluted after the purification (~2.5 ng/µL), not enough to appear on a 1% 
agarose/ethidium bromide gel.  
 After repeating the PCR reaction and purification attempt with similar results, it 
was determined that this was due to formation of primer dimers (Fig. 2.1), which 
inhibited DNA extension. On the other hand, PCR of the small GTPase Rab1, carried out 
simultaneously, proceeded well, as seen on agarose gel. To confirm that the original 
cDNA was correct, it was run in an agarose gel; the resulting band indicated a length of 6 
kb, much longer than expected. A new cDNA was therefore grown from culture as a 
mini-prep, and PCR was run again. To reduce the risk of primer dimer formation, dimers 
were used at reduced concentration. This time, robust amplification was observed by 
agarose gel for both the "S" and "NS" versions.  
 In order to transfer the purified PCR product into suitable destination vectors (Fig 
2.2), TOPO cloning was attempted. PCR product was mixed with TOPO salts, water, and 
destination vector mixed gently and incubated at room temperature for 5 min and placed 
on ice. The usual transformation procedure was then used: 2 µL of the reaction was then 
added to 50 µL competent E. coli CG5 maintenance cells, incubated another 20 minutes 
on ice, heat-shocked for 35 s at 42 ºC and then returned to the ice. The transformed cells 
were then added to 500 µL TB, shaken at 37 ºC for 1 hr, and then plated on selective agar.  
 No transformants were observed from the first of these attempts, so the clonase 
technique was tried as well, with destination vectors pDEST 14, 15, 17, and 49. Entry 
clone (mMICAL-2), destination vector and clonase reaction buffer were combined in TE 




Figure 2.1. Initial PCR amplification of CRMP failed likely due to formation of dimers 






Figure 2.2. Simplified maps of the main vectors used for construct production and protein expression: 





added, and the mixture incubated a further 10 min.  
 Initially this method, too, generated no transformants. However, after varying the 
ratio of PCR product to vector, this reaction appeared successful, with hundreds of 
colonies observed from 100 µL transformed cells per plate. Rab1, curiously, still did not 
transform. The colonies were grown in LB medium overnight and mini-prepped. 
Restriction with BamHI and agarose gel showed a plasmid length of ~6 kb, close to the 
predicted value (Fig. 2.3).  
 At the same time, continued efforts with TOPO cloning appeared to succeed, but 
upon restriction digestion with BamHI the plasmid appeared, unexpectedly, to break into 
two fragments of about 4.5 and 1.5 kb (Fig. 2.4). These transformants were therefore 
deemed unusable as well. TOPO cloning was repeated anew, searching for a suitable 
target vector for the MICAL-2 PCR product. To speed this process, sectors of agar plates 
were streaked with different colonies following transformation, and the colonies PCR 
amplified in search of a band similar to the expected insert. However, no bands were 
observed by agarose gel after PCR.  
 Eventually, after continued repetition, bands of the expected 3 kb length were 
obtained by double restriction of the product of miniprep samples of TOPO plasmids (Fig. 
2.5). However, when these miniprep samples were submitted for sequencing it was found 
that, although they carried considerable areas of sequence alignment with the expected, 
large tracts were missing, including TEV sites. In light of these ongoing difficulties, 






Figure 2.3. Apparently successful initial TOPO cloning. Cleaved plasmid masses correspond 






Figure 2.4. Single digestion with BamHI unexpectedly causes the MICAL-2 containing 










2.3. MICAL-1 cloning and purification. 
 Initially, mouse fl-MICAL-1 DNA was obtained from American Tissue Culture 
(ATCC; Gene ID NC_000076.6) and cloned into a vector which affords an N-terminal 
GST tag cleavable with thrombin pET48 --Novagen Inc. (Fig. 2.2). MICAL-1 
monooxygenase (MICALMO) clone was also available. Both were in BL21 expression cell 
cultures. In preparation for expression and purification, 4 L LB media was made and 
titrated to pH 7 with NaOH, and 1mL aliquots of 1 M IPTG were also prepared for 
induction of cultures. At the same time, plates of LB agar were prepared for future 
selection experiments, containing 25 µM kanamycin sulfate, 100 µM ampicillin sodium 
salt, or 34 µM chloramphenicol (dissolved in ethanol). Some plates also contained both 
kanamycin and chloramphenicol, or ampicillin and chloramphenicol. 
 After autoclaving, each liter of LB was combined with 100 mg ampicillin, 100 µg 
FAD, and 0.15 g DTT (final concentration 1 mM). An inoculation culture of fl-MICAL 
was set up overnight. In the morning, after 1 hr shaking at 210 rpm and 37 ºC to bring the 
media to growth temperature, inoculation was carried out and A600 was measured every 
30 min. Upon reaching A600 of 0.6, the media was moved to 20 ºC, a timepoint sample 
was taken and the remainder induced with 1 mM IPTG overnight. The final absorbances 
of the culture were measured to be ~5.0, based on 10-fold dilutions to keep within the 
linear range of the spectrometer. The cultures were washed with benzamidine 1 mM and 
PBS buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, and pH 
7.3), re-centrifuged and the pellets frozen at -80 ºC. 
 For resuspension of the pellet, pellets were broken by microfluidization in the 
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following way: pellets were thawed on ice, and pellets from each 1 L of culture were 
resuspended with 35 mL of the appropriate buffer for purification of the protein, but with 
the addition of 5 mM MgSO4, 10 µg/mL DNAse, and a tablet of EDTA-free Complete 
protease inhibitor cocktail (Roche pharmaceuticals). The mixture was gently resuspended 
with a glass rod and two presses of a dounce homogenizer, stirred at 4 ºC for 10-15 min. 
and broken using two passes through the microfluidizer with 75 psi of air pressure. 
(Unless otherwise stated, all pellets were processed in this way.) 
 The lysate was clarified by 30 min. spinning in a SS34 rotor at 10,000 rpm, the 
supernatant filtered using a millipore 0.22 µM filter Stericup. Glutathione beads and 
elution buffer were prepared according to manufacturer's instructions, beads were added 
and shaken with the supernatant overnight. Elution was carried out with a gradient of 
glutathione. However, when the fractions were loaded on SDS-PAGE gel, no expression 
was observed. One possible cause of failure was thought to be low dissolved oxygen, due 
to a persistent plateau in A600 reading early in the growth phase. Subsequent cultures 
showed a similar difficulty, with A600 values that were slow to increase or even 
regressed slightly.  
 Another GST column purification of the fl-MICAL pellet showed significant 
amounts of product around the expected ~130 kDa mass when run on a 4-15% SDS-
PAGE gel (Fig. 2.6), suggesting the growth deficiency may not be important to yield. 
Thrombin digestions of the fractions that were candidates for containing GST-MICAL1-
fl were carried out, and free GST was removed by addition of recharged GST beads. The 
flow-through was collected, centrifugally concentrated and analyzed by SDS-PAGE (Fig 











Figure 2.7. Following GST tag cleavage and removal, MICAL is found only in poor 




 congeners, most likely degradation products.  
 Due to ongoing difficulties in GST-tag based purification, MICAL1-fl  (2-1048) 
sequence with Q78K modification to eliminate an internal TEV-cleavage site was codon-
optimized for E. coli expression and synthetized by Genscript Inc including a N-terminal 
TEV site (MTEVQ78K) was cloned into a pET-28 vector, which instead affixes an N-
terminal 6xHis tag for affinity chromatography (Fig 2.2). Further induction attempts were 
carried out in large batches (6L) or, ideally, a fermentor with automated pO2 regulation, 
at 20 ºC. Expression appeared to be counterbalanced strongly by protein degradation, as 
yields proved highly dependent on the amount of time of induction, with timepoints 
showing expression clearly underway within 4 hours of induction but completely lost by 
20 hours. At best, this afforded small but manageable yields of 6xHis-fl-MICAL protein 
(0.5 mg/L) which could then be collected by passage through a His-trap column, elution 
of non-specific binding proteins at 10% (50 mM) imidazole, followed by elution of the fl-
MICAL itself at 50% imidazole. Following dialysis or desalting into 20 mM Tris pH 8.0, 
fl-MICAL protein was purified by binding and elution from a SourceQ anion exchange 
column using a 0-1.0 M NaCl gradient.  
 2.4 CRMP cloning. 
 Mouse CRMP1 cDNA was successfully PCR amplified, producing the expected 
band around 1.7 kb. The product was gel purified and TOPO cloning was carried out. 
Initial cloning produced very few or no colonies, and those there were, when grown in 
minipreps, produced no DNA. Upon repetition and optimization of the protocol with an 
increased number of colonies was observed, and when grown in minipreps and restriction 





Figure 2.8. PCR of CRMP frequently produced a smear of products of approximately the 




this band was contaminated and proved unusable (Fig. 2.8) 
 
 2.5 Plexin expression, purification, and constructs. 
 Plates were streaked with cells carrying clones of mouse Plexin-A1 intracellular 
domain (from ATCC,  GenBank NM_008881) in pDEST-15, gift of Dr. Mario A. 
Bianchet. Seven such colonies were grown in 10 mL LB medium with ampicillin to an 
A600 of 0.6, glycerol stocks were made by adding 15% glycerol to 1 mL and freezing at -
80 ºC, and the remainder was induced with 1 mM IPTG for 3 hr at 37 ºC. At the end the 
culture was pelleted, sonicated and the expression assessed by SDS-PAGE. Although a 
band was expected with the plexin intracellular domain's mass of 75 kDa, no difference 
in general induction before or after IPTG was observed, and the 75 kDa band was not 
distinct (Fig. 2.9).  
 New 10 mL starter cultures were begun from the glycerol stock and used to 
inoculate 1 L each of LB medium with ampicillin, and induced for a longer duration (5 
hr). This time the band at 75 kDa was more distinct, but did not show any increase from 
the addition of IPTG. However, incubation overnight of the cell lysate with Ni-NTA 
beads and elution with 200 mM imidazole, 20 mM Tris, and 0.5 M NaCl allowed 
recovery of a moderate amount of plexin from one of the seven clones (Plex2,  Fig. 2.10). 
This plexin as eluted was relatively impure, consisting of two bands of slightly varying 
mass (~72 and 75 kDa) and two smaller, also closely spaced bands. 
 The 6xHis tag in the construct required cleavage at a TEV site for removal. TEV 
protease was grown at 37 ºC and induced overnight at 20 ºC in 2 L Terrific Broth, 






      
 
Figure 2.9. Expression attempts of the initial TOPO plexin-A1 constructs showed no 
inducibility. Top, five separate clones before induction. Bottom, the same clones after 3h 





Figure 2.10. Despite rather poor solubility limited amounts of plexin-A1 intracellular 






Figure 2.11. TEV purification by SourceS readily produces a highly pure product that 
elutes as a sharp peak. 
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eluted, affording ~90% pure TEV in tens of mg quantities. The TEV was desalted to 50 
mM Tris, 10 mM NaCl, 10% glycerol, pH 7.5 and subjected to further purification on a 
MonoS column, eluting in a sharp peak (Fig. 2.11) and then frozen for storage. 
 In an attempt to increase the yield of plexin, the Plex2 construct was grown to 
much higher cell densities before inducing (A600=1.5). Also longer induction times, and 
reduced amounts of IPTG (0.5 mM) were tried, and showed the same basic problem of 
poor inducibility and low yield. The other six Plex clones, 1 and 3-7, were also test-
induced under these circumstances and showed no advantage over Plex2. In fact, 
surprisingly, it was found that leaving out IPTG altogether had no effect on the level of 
plexin expression, and even slightly increased it (as assessed by the Bradford assay). 
SDS-PAGE gels showed no increase in the 75 kDa band in either the soluble or the total 
fractions (as separated by tabletop centrifugation), with no trend of increase from 0 to 3 
hr after addition of IPTG (Fig. 2.12). 
 As it was clear that little or no useful plexin-A1 expression could be achieved 
with the present construct in pDEST 15, cloning into pDEST 17 and pDEST 49 were 
attempted instead. The clones were grown in 10 mL cultures to an A600 of 0.6 and 
induced with IPTG. However, these constructs too showed constant leaky expression of 
numerous proteins and some plexin, with no induction evident either from SDS-PAGE 
gel or by Bradford assay. Ni-NTA beads were added to the lysates of these test inductions 
in order to concentrate and purify the plexin by elution but very little was recovered.  
 Further attempts to purify plexin from the Plex2 construct met with these same 
obstacles, particularly the appearance of twin bands for plexin, probably due to 





Figure 2.12. Like the TOPO construct, Plex2 construct shows no appreciable increase in 




Eventually the TEV cleavage step was discarded in the interest of increasing the yield of 
the fusion protein. Also, TY medium was tried (per liter, 16 g tryptone, 10 g yeast extract 
5 g NaCl, 2% glucose), to boost induction; inductions at higher A600 and low  
temperature (18 ºC), and added glucose upon induction to assist the LacZ system. Anion 
exchange (MonoQ) was attempted in order to purify out a single band. None of these 
measures had any noticeable effect on plexin induction or yield. 
 At this point, the Plex2 construct, as well as the clonase technology and pDEST 
vectors on which it was based, were abandoned in favor of traditional cloning methods. 
The pDEST 17 vector with plexin insert was grown in a maxi-prep, concentrated 10-fold 
using QiaexII beads, the plexin-A1 gene was excised from pDEST 17 using BamHI and 
NotI and ligated into a variety of pET system vectors. The circular plasmid ran as two 
distinct bands of uncertain mass but BamHI cleavage at one site produced a single band 
at the expected mass, suggesting the two bands represented different supercoiled states. 
Cleavage with both BamHI and EcoRV produced two fragments of the expected lengths 
(4.5 and 1.9 kb,  Fig. 2.13).  
 Cloning of the plexin-A1 insert was carried out in pET 28, pET 32, pET 42 
between the BamHI and either EcoRI or NheI sites. Cloning was tested in the Vector NTI 
software (Invitrogen, v. 10.3.0), which allowed restriction sites to be chosen and maps of 
the intended constructs built. EcoRI was used where possible with BamHI to avoid the 
sequential digestion required when using NheI. For pET28a(+), SacI and NheI were used. 
Because this plasmid includes both N- and C-terminal 6xHis tags, PCR amplification of 
the plexin insert was carried out using two sets of primers (Table 1), depending on 





Figure 2.13. Excision of the PlexA1IC gene from pDEST17 with BamHI and EcoRV 
produces bands of the expected length (1.5 kb for plexin, 4.5 kb for rest of vector). Lane 





agarose closely matching the expected 1.8 kb.  
 Competent GC-5 cells were transformed with pET28a and grown in miniprep, 
providing an ample stock of the destination vector. The plexin PCR product was purified, 
 and both it and pET28a were digested with NheI and SacI. Ligation was carried out 
using a 6:1 insert:vector ratio and GC-5 cells were transformed with the product. The 
colonies produced by transformation with ligations where the plexin insert lacked a stop 
codon were far more numerous than those with a stop codon, but both were collected and 
grew normally, with normal DNA yields (~10 ng/µL). SacI digestion was carried out on 
all clones and assessed by agarose gel, confirming that most colonies were successful 
ligations with the expected length (Fig. 2.14).  
 However, digestion of the stop-codon versions--which should cut in the middle of 
the insert as well as at two sites within pET28a, thus giving three distinctive bands--
showed only a single cleavage, with a single diffuse band as the product. Ligation was 
repeated, using a 3:1 insert:vector ratio. Of the twelve clones grown in miniprep, 
following double digestion with SacI and NheI, only two showed the two expected bands 
(Fig. 2.15); these were labeled "S27" and "S31". Both were sequenced, revealing that S27 
was unusable but S31 perfectly matched with plexin-A1 intracellular region (PlexA1ic) 
ligated into pET28a, with the exception of a T-to-C transversion that proved silent for 
that codon. 
 The pET28a: PlexA1ic clone S31 was transformed into BL21 cells and 
inducibility was assessed by induction of a small sample, sonication of the pellet, 
separation into soluble and total fractions and SDS-PAGE, revealing a very clear band 






Figure 2.14. Ligation of PlexA1ic into pET28a proceeded successfully. Cleavage with 





Figure 2.15. Double-digestion of PlexA1IC : pET28a ligation revealed two clones of 
potentially correct sequence, labeled “PlexAS27” and “PlexAS31”. DNA sequencing 






Figure 2.16. First successful demonstration of inducibility of PlexA1ic, using the 





fraction, with only a minute amount remaining soluble (Fig. 2.16). In an attempt to 
resolve this solubility problem, inductions were tried at lower temperatures, both for 4.5 
hours: 25 ºC and 18 ºC. The lower temperature only marginally improved the amount of 
soluble PlexA1ic as measured by Bradford assay, and negligibly as viewed by SDS-
PAGE (Fig. 2.17). Proceeding with Ni-NTA beads to collect what soluble protein there 
was, eluting and then dialyzing overnight with thrombin to remove the 6xHis tag afforded 
both very low yield of PlexA1ic and incomplete tag cleavage.  
 In the hope of recovering more of the insoluble fraction of plexin, or at least 
solubilizing it so that it could be quantitated, pellets were grown at 25 ºC and broken 
using 0.3% v/v Triton X-100, 5% v/v glycerol (also 50 mM Tris, 150 mM NaCl, 0.1% ß-
mercaptoethanol, pH 8). This increased the amount of PlexA1ic that eluted from Ni-NTA 
beads, however it was unusable, precipitating once the detergent was dialyzed away. The 
solubilizing detergent CHAPS at 0.1% w/v was also tried, with a similar result.  
 For the small amount of PlexA1ic that could be recovered in the soluble fraction, 
thrombin digestion of the 6xHis tag continued to be a problem, with only partial digestion. 
As a control a small amount of another thrombin-cleavable fusion protein, Tc-SPPS, was 
expressed and purified and treated with the same amount of thrombin. Cleavage was 
complete for this protein, indicating that the problem did not lie with the thrombin stock 
or the procedure used (Fig. 2.18). 
 Given the hydrophilicity of histidine, it was thought that an additional, C-terminal 
6xHis tag might improve the solubility. A construct lacking the antisense primer stop 
codon, called NS36, was isolated in the same manner as S31, found to be of correct 





Figure 2.17. Reduced-temperature induction of the PlexAS31 construct does not 






Figure 2.18. Incomplete removal of the 6xHis tag by thrombin was a common problem 
in purification of the PlexAS31 constructs. Successful removal of 6xHis tag from Tc-
SPPS by the same sample of thrombin suggests a problem of structural inaccessibility of 






Figure 2.19. In contrast to the PlexAS31 clone, in which a stop codon prevented 
translation of the C-terminal 6xHis tag, the PlexANS36 clone contained both N- and C-





NS36:pET28 exhibited strong inducibility but no soluble plexin product was observed 
(Fig. 2.19).  
 On the hypothesis that plexin was misfolded and that this was impeding solubility 
 and thrombin cleavage, 6M guanidine hydrochloride was used to gradually unfold, then 
refold the plexin (. 2 mL of 6xHis- PlexA1ic, eluted from Ni-NTA beads at a 
concentration of 0.27 mg/mL, was dialyzed into 6M guanidine HCl for 6 hr and then 
back into Tris + NaCl buffer, pH 8. Thrombin digestion was not improved, even at a level 
of 5 U/mL, indicating that either the problem is not one of misfolding, or that the protein 
does not successfully re-fold. 
 In any event, as a small fraction of plexin could be extracted in the soluble 
fraction, larger induction volumes (>4L) were used and these larger pellets were lysed, 
shaken overnight at 4 ºC with Ni-NTA beads, eluted with 200 mM imidazole and 
dialyzed to remove the imidazole and salt for anion exchange. Typically 1/3 of the total 
protein would precipitate during this dialysis step, and much of the rest during SourceQ 
purification. This left a small amount (~3 mg) of highly pure, though uncleaved 6xHis- 
PlexA1ic (Fig. 2.20).  
 As solubility and cleavage inefficiency continued to render production of 
adequate amounts of PlexA1ic for kinetic studies or crystallization problematic, it was 
decided to move the plexin gene into another plasmid, a pET28b in this case, specially 
modified by inclusion at the N-terminus of a yeast SUMO protein sequence and 
downstream Ulp1 protease cleavage site (Gly-Gly-Ser,  Fig. 2.2). This vector, known as 
pSmt3, was a generous gift of Dr. Christopher Lima, Sloan Kettering Institute. Ulp1 





Figure 2.20. SourceQ purification of the product of the PlexA1ic: pET28a induction. 
Although the large majority of the product was insoluble and much of the remainder 





Krisna Duong-Ly).  
 The PlexA1ic insert was excised from pET28a using SacI and NheI. To 
accommodate the fact that the SUMO sequence was already inserted into pSmt3 using an  
NheI site, the forward plexin primer was changed to incorporate a BamHI site instead. 
PCR, agarose gel purification, restriction of both the PCR product and pSmt3 with 
BamHI and SacI, and ligation were carried out. Sequencing of the clones revealed several 
with perfect fidelity to pSmt3: PlexA1ic, and these were transformed to GC-5 cells, grown 
in miniprep, and then used to transform BL21 cells. They readily induced and showed not 
only higher yield than all constructs previously tried, but far more protein remained 
soluble. SUMO tag removal with Ulp1 also proved much more straightforward (Fig. 
2.21). Purification by SourceQ readily separated Ulp1-cleaved PlexA1ic, giving a single 
very sharp peak. However, when removing salt by dialysis following elution, PlexA1ic 
became unstable and approximately 80% precipitated. This was thought to be due in part 
to intolerance of low salt, combined with the highly soluble and stabilizing SUMO tag. 
 Buffers were further optimized, and it was found that plexin stability post-Ulp1 
cleavage was considerably improved by addition of 0.2 M glycine and 5% glycerol to the 
buffer, and pH adjusted to 7.3-7.7. At least 50 mM NaCl remained necessary for long-
term protein solubility however; brief periods of desalting sufficient to load an anion 
exchange column were tolerated, but storage of hours or more invariably produced 
precipitation. Surprisingly, addition of DTT also appeared to induce precipitation.  
 To increase yield and possibly the folding of the protein, expression was carried 
out at 16 ºC overnight (~16 h), which significantly increased the yield (>8 mg/mL of 





Figure 2.21. Cleavage of the SUMO-PlexA1ic fusion by Ulp1 proceeds almost 
quantitatively, and after dialysis to remove imidazole from the initial His-tag step, 
SUMO is easily removed by shaking with Ni-NTA beads. The result is PlexA1ic (2nd




stages of purification. It was also found that due to the extremely high expression of 
SUMO- PlexA1ic, anion exchange was not necessary for purification; instead the fusion 
protein was retrieved from the lysate using Ni-NTA beads, eluted, cleaved with Ulp1,  
desalted to remove imidazole, and treated with Ni-NTA beads again to remove the 
SUMO tag (which contained the only 6xHis tag in the fusion protein). The result, as 
estimated from SDS-PAGE gel, was protein of >95% purity. This combination of 
methods was deemed very satisfactory and was used for all plexin subsequently produced. 
 
 2.5.1 Plexin-A1 Intracellular Domain Subcloning. 
 To examine the interactions between these domains and other proteins, especially 
fl-MICAL, it was necessary to express isolated subdomains of PlexA1ic as well. Four new 
constructs were chosen, consisting of combinations of the three main parts of PlexA1ic 
(C1 domain, RBD, and C2 domain). These were delineated by the choice of four primer 
sites within the PlexA1ic gene: α, A, B, and ω (Table 1), with the following rationales: 
 C1 alone. Between primer sites α and A (a.a. 1286-1496). The structures of 
Plexin-A3 and -B1 intracellular domains (25,  26) show the C1 and C2 domains closely 
intertwined with the RBD more loosely tethered between them. Furthermore, given that 
C2 is the region of plexin known to interact with fl-MICAL (5,  40), this suggests that 
plexin activation involves a significant shifting of the domain structure to expose or 
create an fl-MICAL binding site. Planned experiments centered around examining 
whether this could physically interact with the C2, and also whether it could act as an 
inhibitor for fl-MICAL activation by plexin, by competing the C2 away from the plexin-
interacting region of fl-MICAL.  
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 C1–RBD. Between primer sites α and B (a.a. 1286-1670). Similar to the purpose 
of C1, but with the RBD included, in case this was necessary for reconstitution of plexin 
activation, or for C1 binding to C2. 
 RBD alone. Between primer sites A and B (a.a. 1496-1670). The RBD alone was 
considered a valuable subject for structural determination in itself and in combination 
with purified Rnd1, with which it is known to bind. This was subsequently achieved by 
Buck et al. in Plexin B1 (34,  35). 
 C2 alone. Between primer sites B and ω (a.a. 1670-1910). As the region of plexin 
thought to facilitate the activation of fl-MICAL, specifically through binding to the C-
terminal autoinhbitory domain, this region of plexin was of particular interest. Under 
current understanding, it seemed plausible that this subdomain might in isolation mimic a 
constitutively activated plexin molecule, its MICAL-binding region being completely 
unhindered by C1 or RBD. It thus could be sufficient to titrate the C-terminus away from 
its auto-inhibitory position, which would then be measurable as an increase in NADPH 
consumption (or F-actin disassembly). 
 The C1, C2, RBD, and C1-RBD segments of PlexA1ic were amplified by PCR 
(with 5% DMSO), giving bands of the expected length (Fig. 2.22) and restriction digested 
and ligated into pET28a. Both PCR from the purified plasmid and sequencing confirmed 
error-free incorporation of the insert for the case of the RBD and C2, while successful 









 However, when incorporated into BL21 cells and induced, the pET28a:RBD 
plasmid showed no trace of induction on gel, while Bradford measurements indicated a 
decrease in total protein upon induction in both soluble and total fractions. After 
numerous efforts to modify the induction conditions in which no sign of the expected 
band could be found, some expression was observed but the protein remained insoluble 
even in detergent (0.3% w/v CHAPS). It was concluded that the protein was inherently 
unstable. Similar difficulties were encountered in the cases of C1–RBD, and C2; C1–
RBD, which expressed well, was not soluble. 
 It was judged that of the four subclones, C2 was the most interesting and further 
attempts focused on producing and studying it alone. Cloning into pSmt3 and PGEX-5x-
1 was carried out and sequencing revealed several clones with no sequence abnormalities. 
SUMO-C2 (and to a lesser extent GST-C2 fusion), visible as a band at 37 kDa, expressed 
robustly at 17 ºC for 20 h, with a slightly more acidic LB medium (no added NaOH), 
producing 7 mg/L, an amount similar to that observed for SUMO- PlexA1ic. Following 
cleavage of the SUMO tag, however, the free C2 proved highly insoluble, with near-
complete loss of the protein. A subsequent search for stabilizing buffer conditions, 
varying salt, pH, and glycerol levels, showed no improvement in this situation.  
 This suggested that the isolated C2, normally found in an intertwined 
configuration with the C1, depends on intramolecular interactions with the other 
subdomains for stability, or in this case, with SUMO. This dependence incidentally raises 
questions as to the validity of studies that have featured expression of the isolated C2 
domain to outline plexin-MICAL interactions, such as (5) and (33). In any event, all 
experiments requiring PlexA1ic C2 henceforth were carried out with the uncleaved fusion. 
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 2.6 MICAL C-terminus (and variants). 
 6xHis-tagged MICALCTD (a.a. 843-1048) was originally cloned from codon-
optimized MICAL-1 gene and ligated into a PRO-EX plasmid by Dr. Tsu-Lan Yeh. Cells 
grew well under ampicillin resistance and induction (17 h at 18 ºC) produced a large 
increase in protein expression. However this expression contained a vast number of non-
specific bands; although overall solubility appeared satisfactory in 150 mM NaCl, 20 mM 
HEPES pH 8, 0.1% Triton, the problem of non-specific bands was not reduced 
appreciably by binding and elution from Ni-NTA, suggesting that many of the bands 
were degradation products still containing the original affinity tag.  
 Further attempts at expression optimization were unavailing, so new primers to 
the CTD were generated and the gene was amplified from the original stock of codon-
optimized fl-MICAL1. The gene was restriction digested and ligated into pSmt3. 
Induction was extremely successful, producing in some cases >15 mg/mL of SUMO-
CTD fusion protein product in ordinary LB after 3 hr at 37 ºC. Binding and elution with 
Ni-NTA beads was unproblematic and, furthermore, Ulp1 cleavage produced none of the 
solubility difficulties occasionally seen with plexin and its subdomains such as C2.  
 As with plexin, because the overwhelming majority of protein produced in 
induction was SUMO-CTD, little purification was subsequently needed. However, anion 
exchange using MonoQ was helpful in removing SUMO and residual impurities. Buffer 
conditions were 50 mM Tris pH 7.3, 5 % glycerol, 0.2 M glycine, 30 mM NaCl for buffer 
A, and 900 mM for buffer B. SUMO eluted in a sharp peak at 19% B, while the elution of 
CTD was centered around 38% B but eluted in a complex profile, with a wide undulating 
plateau with three absorbance maxima (Fig. 2.23). 
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 Notably, the CTD thus purified consisted of two bands of very similar mass, 24 
and 27 kDa as judged by the SDS-PAGE ladder (Fig. 2.24). This two-band problem was 
also observed with the intact SUMO-CTD fusion, ruling out the possibility of unwanted 
proteolysis by Ulp1. Since a monodisperse product was desired, efforts were made at 
isolating one or both of these bands; they were generally not successful, as gel filtration 
lacked sufficient resolution to completely separate proteins differing by only 3 kDa. On 
the other hand, SDS-PAGE of the fractions from MonoQ anion exchange demonstrated 
that a small shoulder of "24 kDa" band eluted before the "27 kDa" began to appear, 
although the vast majority of the two coincided. This difference proved too modest to 
reliably exploit, and varied considerably from one pellet to another despite efforts to 
closely control the conditions of induction and pellet lysis and identify factors that could 
increase the ratio of "24 kDa" to "27 kDa" through slower induction, lower temperature, 
added glucose, addition of 1 mM TCEP during lysis, and so on.  
 It was unclear at this point which of the two bands corresponded to the "correct" 
sequence, although their near-identical anion exchange elution profiles suggested very 
similar sequences. N-terminal sequencing bore out this supposition, showing that both 
bands begin with exactly the same five amino acids--EAIEK, the intended sequence--and 
that therefore the difference must involve the C-terminal end.  






Figure 2.23. A typical MonoQ separation of MICALCTD product. Chromatogram shows 
SUMO eluting from column in a sharp peak at 19 % B, while CTD begins eluting at 34.6 
% B. A final large peak emerges at 55% B. Clearly visible in the gel of the fractions 
(below) are the two separate lengths of the MICALCTD product. Although the two bands 
were extremely hard to separate in large amounts, the lighter “24 kDa” band in some 
cases would elute slightly before the heavier “27kDa” band, allowing a small amount of 








Figure 2.24. Original MICALCTD construct when digested to remove SUMO reveals 
two bands at approximately 24 and 27 kDa. A newer construct, designed to pre-





was correct, but read-through of a UAA stop codon appeared unlikely. It was also 
observed that a mixture of the two bands, if left to stand at room temperature for several 
days, would gradually convert to the shorter, "24 kDa" form. (This phenomenon proved 
to be of little use, as the protein was rendered ineffective by such conditions.) This, taken 
together, suggested proteolytic cleavage, however the presence of protease inhibitor 
cocktail (Complete; Roche, Inc.) and PMSF did not reduce the observed quantity of the 
shorter band. 
 To resolve the identity of the two products, the bands were separated by running 
on SDS-PAGE, transferred to PVDF membrane, cut out and sent for mass spectrometry. 
This analysis showed that the longer band was in fact the complete form, while the 
shorter was formed by loss of the C-terminal 14 residues (Fig. 2.25). Searches of UniProt 
suggested no unique protease cleavage consensus sites in that region, so it may be that the 
truncation is due to a halt in protein translation which sometimes leads to premature 
termination. 
 Once it was clear that the "27 kDa" was the complete sequence attempts were 
made to purify it instead, but although usually more abundant, this proved more difficult 
than obtaining "24 kDa", since the latter always eluted first, contaminating the second 
product. Instead, a new construct was made to overcome the problem. Since the shorter 
product of MICALCTD (called CTD24) had appeared to have the same potency, a new 
primer was designed to pre-emptively truncate the 14 residues in question, thus ensuring 
a monodisperse product. This product, cloned in pSmt3 as with the original CTD DNA, 
was expressed and purified with similar ease and in similar quantity to the latter. 
Moreover, SDS-PAGE gels indicated the product consisted of a single band (Fig. 2.24). 
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Figure 2.25. Mass spectrometric analysis of the “24 kDa” and “27 kDa” bands produced 
by the MICALCTD construct. Both clearly derive from the intended sequence of 





 In addition to the original SUMO-MICALCTD (SUMO-CTD) and SUMO-CTD24 
constructs, three variants on the CTD were pursued. The first, called "PPPCTD" (a.a. 
769-1048) included the proline-rich, SH3-domain-binding region of MICAL1. It was 
thought that, due to this region's interactions with CasL in particular, its inclusion may 
help modulate the auto-inhibitory function of the MICAL CTD itself.  
 Another, shorter version of the MICAL1 CTD, "CTDnoE13" (a.a. 875-1048) 
omitted the 13-glutamate stretch at the N-terminal end of the CTD. This, it was hoped, 
would give clues as to the role of this unusual sequence feature in MICAL1 
autoinhibition, and possibly in the stability of the CTD itself.  
 Finally, a double mutant was made containing A934P & T935P point mutations. 
These lie in the heart of the (predicted) coiled-coil helices of the CTD and so, by 
disrupting them with prolines, this protein was intended as a control to confirm the 
necessity of this structure for proper inhibition. Though cloning proceeded without 
problems and sequence was verified, none of these three constructs (except PPPCTD, in 
pET28a--Fig. 2.26) showed detectable protein expression and they were not pursued 
further. PPPCTD proved highly difficult to render soluble and was not pursued further. 
 2.7 Rnd1. 
 As one of a small group of GTP-binding proteins known to bind and activate the 
RBD of Plexin-A1, expression of Rnd1 is likely a necessity for any effort to reconstitute 
plexin activation. Rnd1 was originally ordered from Open Biosystems as a clone in a 





Figure 2.26. Successful induction of the C-terminal MICAL “PPPCTD” construct, 




but proved completely insoluble, even under buffer conditions under which Rnd1, far 
from being unstable, is known to crystallize (35,  63).  
 It has been documented that rho-family GTPases, contrary to the general rule that 
such smaller proteins are often more stable and easier to crystallize, are actually very 
sensitive to buffer conditions and presence of ligand (64). It was therefore supposed that 
addition of GTP might, upon binding, lock the protein into a stabler conformation and 
allow solubilization. This, as well as urea refolding attempts, met with no success. 
Further analysis of the sequence revealed that the sequence on which the construct was 
based (with Entrez accession number BU048531), despite being labeled as "mouse Rnd1", 
did not represent the physiological protein; in particular, a lengthy repeat of very 
hydrophobic residues--cysteines and valines--had been incorporated at the C-terminus.  
 Once this problem was recognized, the correct sequence (NP_766200.1) was 
located, and this time synthesized in codon-optimized form by GenScript. Residues 5 to 
200 of 232 were used for this construct, as this version had been previously crystallized 
and shown to bind GTP (35), and was therefore expected to be more stable. Initially, 
cloned into pET28a, no growth was observed; after the product was validated by 
sequencing, it was transferred into pET 22a, 32a, 42a, and pSmt3. All save pET32a 
showed no expression, and pSmt3 did not even produce colonies. pET32a, however, 
expressed vigorously after 15 h at 16 ºC (Fig. 2.27).  
 The product of pET32a expression is a fusion, containing an N-terminal 
thioredoxin (THX) tag, and this may have aided solubility. The fusion was easily 
removed from the lysates by nickel affinity beads due to an internal 6xHis tag, and 





Figure 2.27. THX-Rnd1 fusion expresses readily in pET32a vector, and thrombin 





after overnight digestion at 4 ºC with PMSF. Buffer conditions were the same as 
published for crystallization: 50 mM Tris HCl, 150 mM NaCl, 5 mM MgCl2, 5 mM DTT, 
pH 7.5. The THX-6xHis tag was easily separated from Rnd1 by anion exchange 
chromatography over a gradient of 0.1-1.0 M NaCl, with THX eluting at 8 % buffer B 
(90 mM NaCl) and Rnd1 at 17 % B. 
 Excellent yields (~8 mg/L) and purities (>95%) were achieved by these methods, 
and as a final step, Rnd1 was loaded with GTP by incubation overnight at 4 ºC in 3 mM 
GTP (Sigma) After concentration to 5 mg/mL, 15% glycerol was added and the stocks 










Solubility Product size 
PlexA1-intracellular 
in pET-28a 
good (>5 mg/L) very good poor 73 kDa 
PlexinA1-RBD in pET-
28a 
none seen n/a n/a 20 kDa 
PlexinA1-C1 in pET28a poor n/a n/a 30 kDa 
PlexinA1-C1-RBD in 
pET28a 
poor n/a n/a 50 kDa 
PlexinA1-C2 in pSmt3 
(SUMO) 






very good (>10 
mg/L) 










excellent 38/35 kDa 
CTD24 in pSmt3 excellent (>15 
mg/L) 
excellent—single 





Rnd1 in pET-32a very good (>8 
mg/L) 
very good very good 36 kDa 
HIF-2α PAS-B in 
PROEX (GST tag) 








Chapter 3: Results. 
 3.1 HPLC/gel filtration.  
 A key aspect of the models of plexin activation and also of MICAL auto-
inhibition is that they imply physical association of certain proteins. For example, 
MICALMO is anticipated to associate with the MICALCTD and thus be inhibited; plexin is 
thought to dimerize and also to bind Rnd1 to its RBD region; and the C2 domain of 
plexin has been identified by co-immunoprecipiation (5,  40) as the region whereby it 
interacts with MICAL-CTD, lifting auto-inhibition. These aspects were investigated by 
HPLC and gel filtration experiments.  
 To detect the formation of a complex between MICAL1-CTD and PlexA1ic, after 
zeroing with buffer, a standard curve was produced by injecting 1:1, and 6:1 molar 
mixtures onto a Bio-Rad HPLC column at a rate of 1 ml/min. Volumes of elution for 
each peak were measured and plotted, and fitted to a logarithmic curve. Next, freshly 
cleaved SUMO-CTD and SUMO- PlexA1ic were injected and elution volumes were 
measured for all of the major peaks observed (Fig. 3.1). These were compared to the peak 
profile created by a 1:1 molar mixture of the two proteins.  
 Results in all three cases showed a very clear peak for SUMO (12 kDa) which, 
consistent with its small size, eluted last at 13.6 mL and thus functioned as a standard. 
For plexin alone, there was also a large and distinct peak at 9.3 mL, indicating a mass of 
66 kDa, close to the actual mass of 70 kDa. Results with CTD alone were more complex 
and difficult to interpret. Instead of the expected single peak for a 24 kDa protein, which 
should elute ahead of the heavier PlexA1ic but well before SUMO, there were instead two 





Figure 3.1. Initial HPLC experiments showing calculated MW corresponding well to 
plexin (“P”, ~66 kDa), and SUMO (~11 kDa). MICALCTD (“M”) on the other hand 




respectively. These large values are indicative of the formation of large oligomers 
(trimers and above) by the CTD.  
 The combination of PlexA1ic and CTD, notably, showed some changes in these 
features, with the intensity of the plexin peak reduced by half relative to SUMO; the large 
215 kDa peak observed in the CTD alone reduced by three-fourths and the 79 kDa 
became indistinguishable. This suggests that PlexA1ic is able to disrupt aggregates of 
CTD, perhaps in favor of formation of a complex. At the same time, a moderately strong 
peak appeared at 7.8 mL, not seen in either component preparations. This new peak 
however corresponded to a mass of 117 kDa, too large to be accounted for by a 1:1 
plexin:CTD complex which would be only 94 kDa (although a 1:2 complex would give 
116 kDa, a close fit). 
 Subsequent experiments, however, showed no new peaks appear upon 
combination and of the two proteins, arguing against formation of a complex (Fig. 3.2). 
This may not be inconsistent with the models of plexin activation however, since no 
GTP-bound Rnd1 was present in these experiments. 
 Further HPLC experiments showed that addition of 20 mM BME could change 
the distribution of oligomers, dramatically shifting the preponderance of CTD from the 
215-kDa band to the 79-kDa. However, the fact that the CTD construct in question only 
contains one cysteine makes it uncertain how redox-sensitive oligomers larger than 
dimers could be formed.  
 Related attempts were made with size-exclusion FPLC, both to confirm the HPLC 
results and to address the difficulties in separating the two MICAL-CTD bands. No 





Figure 3.2. Further HPLC experiments show distinct profiles for PlexA1ic (orange 
peaks, “P”) and MICALCTD (green peaks, “M”). However, the 1:1 molar mixture of 




to that from HPLC, with three main "humps" rather than peaks (Fig. 3.3). SDS gel 
however indicated that the two latest-eluting of these contained little or no protein, 
suggesting that all CTD actually traveled as the 215-kDa oligomer.  
 Another subject of importance was whether the interaction of CTD with the rest 
of the MICAL molecule could be detected as a complex. Therefore, three experiments 
were carried out on a Superose 6 column, with 200 µL containing one or both of 1.5 
mg/mL of CTD and 3 mg/mL of MICALMO. Although the CTD continued to run as a 
heavier-than-expected oligomeric form, eluting ahead of the 54 kDa MICALMO, a small, 
early-eluting peak was observable ahead of both the CTD and MICALMO peaks (Fig. 3.4), 
suggesting that enough monomeric CTD remained available in solution to produce 
significant amounts of the expected complex with MICALMO. 
 The activation of plexin is supposed to be partially dependent on its dimerization 
(33). Since many of the kinetics experiments were to be carried out under the supposition 
that this dimerization can be made spontaneous by adding enough plexin to the solution, 
it was important to confirm that the plexin concentrations used in those experiments were 
sufficient to produce a significant amount of the dimerized form.  
 Standards used were vitamin B12 (1 kDa), myoglobin (17 kDa), ovalbumin (44 
kDa), gamma-globulin (158 kDa), and thyroglobulin (670 kDa), while the sample 
consisted of 500 µM of PlexA1ic at 2 µM concentration. Next to the main plexin peak--
whose calculated mass of 71.5 kDa closely corresponded to the actual value of 70.1 kDa-
-was a significant "shoulder" peak whose center (as detected by AKTA UNICORN 5.0 
software) corresponded to 157.5 kDa, very close to the expected 140 kDa for a dimer, 





Figure 3.3. Consistent with HPLC, Superose12 analysis of MICALCTD also suggests 
large oligomers with the main peak eluting close to the void volume (about 12 mL). 







Figure 3.4. Analysis of complex formation between MICALCTD and MICALMO. Three 
consecutive Superose6 injections are shown. First, MICALMO and MICALCTD are run 
separately. The latter again runs as an oligomer, eluting in a smaller volume than the 54 
kDa MICALMO despite having half the molar mass. When the two are combined, two 





 3.2 Kinetics. 
 Central to the question of the effect of F-actin and the MICAL-CTD on the 
activity of the MICAL monooxygenase is the rate of NADPH consumption by the latter. 
This is readily monitored due to the strong absorption at 340 nm of NADPH, which is 
absent in the reaction by-product, NADP. Briefly, the proteins involved in the experiment 
in question were combined at 10/9 desired final concentration, then fresh NADPH was 
prepared at 10x desired concentration (after A340 measurements to check for 
degradation). Each 100 µL cuvette was rinsed thoroughly with ddH2O and ethanol, dried 
with pressurized air, and 99 µL of the desired protein mixture was added; the 
spectrophotometer was blanked, and 11 µL of 10x NADPH added to start the reaction, 
then vigorously mixed by pipetting up and down for 5 s to homogenize the mixture as 
quickly and thoroughly as possible. Reaction progress was then monitored 
spectrophotometrically for 15 min and each reaction was carried out in triplicate. In 
general, experiments consisted of five triplicates at [NADPH] ranging from 10 to 150 µM. 
The results for the different protein mixtures were as follows, (in all cases with [MICAL] 
= 0.1 µM): 
 a) MICALMO, MICALMO-CH, and CTD. 
 In the presence of increasing amounts of MICAL-CTD, both MICALMO and 
MICALMO-CH showed very strong (Kd ~ 300 nM) inhibition, underscoring the hypothesis 
that MICAL-CTD is an auto-inhibitory domain. 
 b) MICALMO-CH alone, and with F-actin. 
 As reported elsewhere (43,  59,  65), MICALMO-CH showed a large increase in 
NADPH consumption in the presence of F-actin, suggesting that this is at least one 
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physiological substrate of the enzyme. However the observed acceleration, while large, 
was substantially less than some reports, which claim a >100-fold increase. 
 c) fl-MICAL alone, and with F-actin. 
 fl-MICAL consumed NADPH about ten-fold slower than the constructs lacking 
the CTD did under similar conditions (Fig. 4.1a). This reduced activity is consistent with 
an auto-inhibited state owing to the CTD, perhaps blocking substrate access. 
Unexpectedly however, this auto-inhibited state could be largely abolished by addition of 
F-actin, whereupon the enzyme showed kinetics about 40% as fast as the CTD-free 
constructs (Fig. 4.4). Since F-actin can activate fl-MICAL, it appears that physiological 
activation of fl-MICAL's F-actin disassembly function may involve displacement of 
another inhibitory molecule, not of the CTD itself. 
 d) fl-MICAL with PlexA1ic and Rnd1*GTP. 
 When 1 µM PlexA1ic was added to fl-MICAL, a roughly 30% increase in velocity 
was observed. Inclusion of Rnd1*GTP in the mixture led to nearly a doubling of velocity. 
Both effects were considerably larger than that seen with lysozyme controls (Fig. 4.6b), 
suggesting that these two factors can indeed significantly activate the auto-inhbited 
MICAL monooxygenase. Surprisingly however, no increase in velocity was detectable 
from these two factors when F-actin was already present (Fig. 4.7a). Thus, it is unlikely 
that these factors alone are sufficient for the activation of F-actin disassembly under 
physiological conditions. 
 e) fl-MICAL with CasL SH3 and F-actin.  
 CasL is known to interact both with MICAL and with vimentin, raising the 
possibility that it plays a role in activating fl-MICAL's monooxygenase to disassemble F-
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actin in the interior of cells. But, contrary to expectations, the presence of 1 µM of CasL 
SH3 inhibited the NADPH consumption of fl-MICAL on F-actin by about six-fold.  
 (For more information, see "Methods" section of Chapter 3.) 
 3.3 Co-sedimentation. 
 It is known that MICAL is an actin-binding protein, and in particular the 
MICALMO, MICALMO-CH , and MICALMO-CH-LIM have been shown to co-sediment with F-
actin. Given the reported auto-inhibitory role of the MICAL CTD region (5,  40), it 
seemed plausible that this region might control the actin binding of MICAL as well as its 
monooxygenase activity.  
 To test this, 1 µM MICAL construct, 3-5 µM of MICAL-CTD, and 5 µM of G-
actin were combined in a G-actin buffer of 5 mM Tris, pH 8, 0.2 mM CaCl2, mixed by 
pipetting up and down, and then initiating actin polymerization by adding 5 µL 10x 
polymerization buffer (500 mM KCl, 20 mM MgCl2, 10 mM ATP) to a total volume of 
50 µL. Samples were incubated at room temperature for 25-30 min to allow 
polymerization to reach a steady state, and ultracentrifuged at 100,000 g in a TLA-100 
rotor for 25 min. Supernatants were carefully pipetted from the top to avoid disturbing 
the pelleted actin fraction, which was then solubilized by addition of 50 µL of Laemmli 
buffer and vigorous pipetting. Both pellets and supernatants were then briefly incubated 
at 95 ºC before processing by SDS gel to assess the protein constituents of the fractions. 
This methodology had already been employed in (59) to show that MICALMO-CH is 
capable of binding and disassembling F-actin in vitro. 
 The first experiments, conducted with the original CTD construct, clearly show a 
displacement effect, with both the MICALMO and MICALMO-CH completely associating 
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with the F-actin pellet under ordinary conditions but the reverse taking place when CTD 
is present (Fig. 3.5). There was variation in the strength of the effect depending mostly on 
the batch of MICALCTD being used, but it was possible to reproduce the result repeatedly 
(Fig. 3.6), including with MICALMO-CH-LIM (Fig. 3.7), although in the case of that construct 
the batch variability issues were more significant. In particular, the pre-truncated CTD 
(CTD24), while producing a single clear band and in theory identical to the shorter band 
produced by the original construct--which in turn had been isolated in small amounts and 
shown to be effective at actin displacement--seemed somewhat less effective at actin 
displacement.  
 The CTD24 product showed a wider range of displacement potency, and was far 
more likely to co-sediment with the actin or even to pellet by itself. Investigation of the 
purification method by MonoQ showed that, while the original CTD product eluted over 
a very broad peak or combination of peaks and appeared indistinguishable by gel, 
different regions of this peak behaved very differently in terms of displacement of 
MICALMO-Ch from F-actin, and their own adhesion to F-actin: CTD that eluted from the 
MonoQ at the first broad peak at 34.8% buffer B (343 mM NaCl) was active, as was that 
from 39% B, while CTD that eluted at 55% B did not block actin binding and itself stuck 
to actin (Fig. 3.8). Some of the variation could be attributed to differences from one 
MICAL batch to another, with significant amounts of MICAL pelleting on its own in 
some cases. However, introducing an initial centrifugation step to remove this insoluble 
MICAL fraction, though it did produce a well-behaved MICAL that bound F-actin and 






Figure 3.5. Evidence of MICALCTD’s ability to abrogate F-actin binding by MICAL.  
While MICALMO readily binds F-actin and pellets with it, addition of MICALCTD (here 
still containing SUMO from Ulp1 cleavage as well as both 24 kDa and 27 kDa products) 
is sufficient to almost completely drive MICALMO into the supernatant (s). Control 




re 3.6. Smaller quantities of MICALCTD still suffice to displace significant amounts of 













Figure 3.8. The lower-weight product of MICALCTD expression, when purified, is 
sufficient to produce F-actin displacement. On the other hand, although MICALCTD 
elutes through the range of 34-55%B, the actin displacement ability of the MICALCTD 
decreases greatly toward the end of this range, with later-eluting protein sticking to F-




observed in the remaining soluble fraction (Fig. 3.9). 
 Moreover, even such commonplace procedures as flash-freezing with glycerol for 
storage, or 48 h storage at 4 ºC seemed able to convert the CTD into a non-displacing 
form that precipitated by itself at 100,000 g and was useless for actin-displacement. The 
behavior, wherein active samples of the protein might remain stable for weeks and then 
within 1-3 days convert to the ineffective form (at an accelerating rate,  Fig. 3.10), 
suggested an autocatalytic process of misfolding. 
 To address the question of whether the displacement effect as observed owed to 
the CTD protein's structure itself or just to the intense negative charge of the 
polyglutamate stretch which precedes the predicted coiled-coil, the polyglutamate stretch 
was synthesized as a peptide ("E13") and the co-sedimentation experiment was conducted 
using it instead of the CTD. No displacement of MICALMO was observed by the E13 
peptide in these experiments. 
 Since the binding of MICAL constructs to F-actin remained a robust observation 
throughout these experiments, a series of increasing MICAL concentrations was 
undertaken to quantify the stoichiometry of this interaction. Densitometry showed near-
complete binding to 5 µM F-actin for concentrations of MICALMO up to 1 µM; thereafter, 
a steadily increasing fraction of the total was found in the soluble fraction, with 50% of 
the MICAL remaining in the soluble fraction at an initial concentration of Kd ~ 3.5 µM 
(Fig. 3.11).  MICALMO-CH showed a similar pattern but with a somewhat higher Kd (>5 
µM,  Fig. 3.12). 
 Recent evidence shows that MICAL is involved in actin-disassembly (43,  59,  





Figure 3.9. Due to batch variations in the aggregation state of MICAL protein, an initial 
centrifugation step was added to the actin-displacement protocol to pellet out any 
aggregate.  Supernatants were collected and used in the protocol as normally. 






Figure 3.10. MICALCTD and particularly the truncated form CTD 24 convert readily to 
an alternate form that does not displace MICAL from F-actin and also co-precipitates 
with actin. However, overnight dialysis in 8 M urea and re-dialysis into the original 






Figure 3.11. Concentration series assessing binding of MICALMO to F-actin. 50% 
binding and hence Kd is at approximately 4 µM MICALMO, while saturation of the actin 
begins at approximately 2 µM MICALMO, suggesting 2:5 binding stoichiometry. At 






Figure 3.12. Concentration series assessing binding of MICALMO-CH to F-actin. 50% 
binding and hence Kd is achieved at >5 µM MICALMO, while saturation of the actin 
begins at approximately 2.5 µM MICALMO-CH, suggesting 1:2 binding stoichiometry. At 
right, CTD24 displaces MICALMO-CH from F-actin. 
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The mechanism of this reaction requires consumption of reducing equivalents of NADPH. 
Indeed, it has been shown in vitro that upon addition of NADPH, F-actin in the presence 
of MICALMO-CH is rapidly disassembled, and ceases to sediment upon ultracentrifugation 
(59). This methodology was adapted in order to assess the effects of the MICAL-CTD on 
this disassembly activity: 1 µM of MICAL construct was combined with 5 µM G-actin, 
polymerization buffer was added and the mixture allowed 30 min at room temperature to 
fully polymerize, whereupon 50 µM NADPH was introduced and the mixture allowed to 
incubate 100 min.  
 The actin-disassembly effect was readily reproduced, with large amounts of actin 
appearing in the supernatant fraction (Fig. 4.3) compared to control without NADPH. 
Notably, although at least half and usually a majority of the F-actin was disassembled in 
each attempt, a significant amount always remained polymerized, possibly supporting the 
contention that F-actin disassembly by MICAL is a steady-state, rather than an 
irreversible process. Also, contrary to expectations of its function as an auto-inhibitory 
domain, addition of CTD even in 5-fold molar excess to MICAL had no noticeable effect 
on F-actin disassembly by MICALMO-CH in the presence of NADPH (Fig. 3.13); the same 
was true when 1 µM PlexA1ic + 1 µM Rnd1*GTP were present (Fig. 4.7b).  
 In stark contrast, fl-MICAL showed binding to F-actin but produced no noticeable 
F-actin disassembly with NADPH, even over timescales up to 4 hr (54). These 
conflicting results leave the role of the CTD in regulating F-actin disassembly uncertain; 
it may merely reflect misfolding of the purified CTD, or it may indicate a requirement of 
some intramolecular interactions not available from the combination of MICALMO-CH and 





Figure 3.13. F-actin is disassembled by MICALMO-CH in the presence of NADPH. The 





 3.4 CTD refolding. 
 The tendency of CTD to either remain in the supernatant and cause MICALMO 
disassociation from F-actin, or to pellet completely and have no effect on MICALMO 
association with actin, suggested there may be two distinct phases in which the CTD may 
exist. In order to convert the pelleting, non-disassociating phase back to the original, 
restoring the diminished actin-displacement capability of the MICAL-CTD, refolding of 
the protein was attempted. CTD that had noticeably lost its potency was placed in a 10 
kDa MWCO snake skin dialysis membrane and dialyzed overnight into 8 M urea with 5 
mM BME, then dialyzed back to the usual buffer of 300 mM NaCl, 50 mM Tris, 5 % 
glycerol, pH 7.5. This procedure produced a marked recovery of the actin-displacement 
ability of the MICAL-CTD (Fig. 3.14). In addition, refolded CTD ceased to co-
precipitate with actin. In connection with this idea, denaturing lysis was investigated as a 
way of breaking the pellet and refolding all the harvested protein at once, thus increasing 
the initial potency. In contrast to refolding of the already purified protein, this method 
produced no noticeable change in displacement by the CTD so produced and it was 
abandoned. 
 Effectiveness of refolding tended to vary dramatically from batch to batch and 
especially with the construct being used. While the original CTD construct with its two-
band product showed major improvement in actin displacement and a decrease in actin 
co-sedimentation upon refolding, in the case of the pre-truncated CTD24 construct 
frequently halting of co-sedimentation of the CTD24 was observed, but with limited 





Figure 3.14. MICALCTD within a few days typically loses its ability to displace MICAL 
constructs from F-actin and begins to adhere to F-actin. The urea re-folded MICALCTD 




 3.5 H2O2 production measurements. 
 It is understood that the molar ratio of NADPH consumption to hydrogen 
peroxide production in the NADPH oxidase reaction of MICALMO is 1:1, both on 
mechanistic and experimental grounds (44). However it follows from similar grounds that, 
if MICAL does indeed use reducing equivalents to oxidize methionine residues on actin, 
this should be accompanied by a substantial drop in H2O2 production per NADPH. 
However, the standard Amplex Red assay for H2O2 has been found to produce 
artifactually high readings in some cases (65) and also requires a more complicated 
procedure to compare the two, since all NADPH must be removed before it is carried out. 
Instead, a non-enzymatic assay based on the peroxide-driven oxidation of Fe(II) ion to 
Fe(III), coupled to binding with xylenol orange to produce a violet product (absorption 
peak at 560 nm), was employed. 
 To distinguish the differences in H2O2 production by MICAL with or without its 
auto-inhibitory domain intact, and also how the presence of actin alters this production, 
four distinct formulations were used in the experiment, labeled C1, C2, D1, and D2 for 
brevity. Their compositions were as follows: C1 contained 0.1 µM MICALMO-CH, 50 mM 
KCl, 2 mM MgCl2, 1 mM ATP, 100 mM NaCl, and 20 mM Tris, pH 7. C2 was identical 
to C1, except for the inclusion of 5 µM of F-actin. D1 was identical to C1 except in 
containing 0.1 µM fl-MICAL instead of MICALMO-CH, while D2 was identical to D1 
except for the inclusion of 5 µM of F-actin. 
 Standard curves were prepared using each of the four preparations, combined with 
0, 2, 4, 6, or 8 µM H2O2, each in triplicate. The H2O2 stock was measured in triplicate as 
well, based on an absorption coefficient of 43.6 /M/cm at 240 nm. 10 µM of each 
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preparation was added to 100 µM of xylenol orange working reagent, allowed to incubate 
at room temperature for 30 min., and the absorbance at 560 nm measured. 
 Initially, difficulties were encountered concerning the reproducibility of the 
standard curves, without which quantitation of H2O2 production would be impossible. 
However it soon became apparent from repeated attempts to create definitive standard 
curves for each of the four formulations that this lack of reproducibility stemmed almost 
entirely from the variability of the y-intercepts due to the combination of small variations 
in pipetting and instrument drift; the slope of the curves, by contrast, consistently fell 
within the range 0.009-0.011 A560/µM, with an average value very close to 0.0105 
A560/µM. Therefore, this slope value was used henceforth, while for each subsequent 
experiment, freshly prepared C1, C2, D1 or D2 (to which no NADPH had been added 
and which thus could be assumed to contain no H2O2) was used as the zero for A560 
readings, in effect making the y-intercept of the standard curve equal to zero.  
 Reactions were followed at 340 nm to gauge the NADPH consumption. Because 
of a slight actin-bundling effect upon addition of MICAL that caused a slow artifactual 
rise in the measured A340, reaction formulations containing F-actin (C2 and D2) were 
processed in the peroxide assay in 15 min or less after addition of NADPH to start the 
reaction, during which time the bundling effect remained less than 5% of total absorbance. 
In the case of the D1 formulation, on the other hand, the reaction of fl-MICAL in the 
absence of F-actin proved so slow that a longer time course (45 min) was needed to 
generate enough H2O2 to produce a reliable reading on the xylenol orange assay.  
 These results, in combination with measurements of total NADPH consumption, 
consistently showed a drop in the NADPH/ H2O2 ratio (in some cases as large as 66%) 
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for the combination of MICALMO-CH and F-actin (C2). All other formulations showed 
little or no effect on the ratio, suggesting that only MICAL lacking the auto-inhibitiory 
function was capable of modifying F-actin. 
 3.6 Pull-down and IP. 
 As a method of detecting the association of PlexA1ic and MICAL-CTD, pull-
down experiments were attempted. These initially focused on the methodology of binding 
either SUMO- PlexA1ic or SUMO-CTD with an anti-SUMO antibody, collecting and 
eluting it with protein A beads, then examining the eluate for binding partners. In most of 
these experiments, the plexin C2 construct--of which small amounts could sometimes be 
obtained by either leaving the SUMO tag uncleaved, or by expression in a PGEX-5X-1 
vector and similarly leaving the GST tag on--was used mostly, as it was thought more 
likely to provide an open binding site for the CTD. However, the results were generally 
inconclusive. For example, while SUMO-CTD or SUMO-C2 could occasionally (barely) 
be observed in the eluted fraction from the protein A beads--implying 
immunoprecipitation had succeeded--no binding partner (in this case GST-C2 or cleaved 
CTD, respectively) was seen to accompany it by SDS-PAGE. Various pH conditions 
(7.5-8.0) and salt concentrations were tried, without significant change in result. 
 The seeming failure to detect interaction between C2 and CTD may have simply 
been due to the instability of the C2 domain in the absence of the C1, in light of the close 
structural interdependence of C1 and C2 in the full intracellular plexin structure (25,  26). 
Further experiments were therefore attempted with SUMO- PlexA1ic. Also, to simplify 
the procedure, the immunoprecipitation aspect was eliminated by resorting to a pull-down  
scheme, whereby 6xHis-tagged fusion was incubated with putative binding partner with 
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no tag. These experiments showed similarly ambiguous results to the 
immunoprecipitations however. 
 3.7 Crystallization. 
 Crystallization trials were carried out on the following proteins and protein 
combinations: PlexA1ic, CTD, CTD24, and MICALMO with CTD (varying molar ratios). 
In the case of PlexA1ic, in addition to 96-well hanging-drop screens available from 
suppliers Jena, Qiagen, and Hampton, a sample of PlexA1ic was sent to the Hauptmann-
Woodward High-Throughput Screening Center in Buffalo, NY for crystallization 
screening under oil. None of the conditions screened produced strong signs of crystal 
formation, though a few examples of crystalline precipitation were investigated but also 
did not yield improvement. This may have been due to an insufficient concentration of 
plexin (8.8 mg/mL). Upon publication of the plexin-A3 intracellular domain structure 
(25)--which shares >80% sequence identity with plexin-A1--further efforts in this area 
were postponed. 
 Because of the difficulty in isolating a single pure band from the original CTD 
construct (and because of the obvious importance of this for crystallization trials), few 
conditions were screened for the original CTD construct. The CTD24 construct, being 
easily expressed in large amounts and readily purified as a single band, was tested more 
thoroughly for crystallization. Surprisingly, even after SUMO tag removal the protein 
continued to exhibit an extremely high solubility, in excess of 25 mg/mL being achieved. 
This solubility militated against crystallization or even precipitation however, with only a 
small minority showing any signs of precipitate even a week or more after the trays were 
prepared. (This was part of the motivation for attempting the CTD construct lacking the 
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polyglutamate stretch, as this creates an exceptionally hydrophilic moiety within the 
molecule.) 
 Co-crystallization trials using CTD combined with MICALMO exploring 
conditions similar to those previously used to crystallize MICALMO (21% PEG 4000, 0.1 
M Na(CH3COO), 16% glycerol, 1 mM EGTA, pH 5) alone, reliably produced yellow, 
needle-shaped crystals (Fig. 3.16). However, the formation of these crystals dramatically 
decreased at molar ratios of more than 1 CTD:6 MICALMO. Since any MICAL-CTD 
complex is strongly suspected to have a 1:1 stoichiometry, this seemed to argue against 
their being true co-crystals. Furthermore, their crystal morphology was extremely similar 
to that of pure MICALMO crystals. These crystals were very small and when mounted and 
irradiated using the home X-ray source, showed very poor or no diffraction (>10 Å). 











 3.8 ITC. 
 In order to provide complementary evidence for dimerization as well as to 
determine thermodynamic parameters of the interaction that could not be discovered by 
HPLC or size-exclusion alone, isothermal titration calorimetry (ITC) was carried out with 
MICALMO and MICAL-CTD. 
 In the first ITC run, zero enthalpy change (∆H=0) was observed upon addition of 
CTD in tenfold excess to a solution of MICALMO. However, it was thought that in this 
case the concentrations of the proteins might have been too small for the heat of their 
association to be detected; therefore, the experiments were repeated with a tenfold 
increase in the concentration of both proteins (9.7 µM MICALMO in the cell; 118 µM 
CTD in syringe). In this run, too, zero enthalpy change was observed.  
 This contrasted with the apparent formation of an MO:CTD peak on size 
exclusion, and with the observations of CTD's ability to displace F-actin from MICAL; 
on the other hand it supported the HPLC results showing no new "complex" peak and 
those co-sedimentations where little CTD effect could be observed. It remained unclear 
how to interpret the result--whether the proteins used in the ITC experiments were 






Chapter 4: Plexin-A1 Intracellular Domain and Rnd1 Together Suffice to Lift 
Autoinhibition of MICAL-1's Monooxygenase, but not its Actin-Disassembling 
Activities. 
(Adapted from Simon O. et al, 2014) 
ABSTRACT. 
 MICALs are large multidomain proteins implicated in axon guidance, signal 
transduction and actin remodeling. Moreover, the N-terminal domain of MICAL has a 
potent monooxygenase activity. Recent studies have put forward a model of MICAL 
activation and control where MICAL's monooxygenase activity is auto-inhibited by its C-
terminal domain (CTD). This inhibition is lifted when Plexin dimerizes, binds small 
GTPases, and interacts with CTD. Furthermore, work with MICAL lacking the CTD has 
revealed it to have a potent actin-disassembling activity. Using kinetics measurements, 
co-sedimentation experiments, and measurements of H2O2 production, we find that the 
combination of GTP-bound Rnd1 and the intracellular domain of Plexin A1 does 
significantly increase MICAL-1 (fl-MICAL) monooxygenase activity compared to its 
auto-inhibited state. However, with respect to its actin-disassembling activity we find no 
discernible effect. Furthermore, we find that Plexin and Rnd1 are not necessary for 
MICAL binding to F-actin, and that while such binding considerably accelerates NADPH 
consumption, this activity is not associated with actin disassembly. Based on these 







 In the course of neuronal development in the embryo, or in the re-innervation of 
damaged tissues, precise location and direction information must be continuously 
available to extending axons for them to properly innervate their targets. This complex 
requirement is thought to be met through the establishment and sensing of gradients of a 
plethora of morphogen and guidance molecules. Several protein families, each 
comprising dozens of proteins termed "axon guidance cues", are known to serve in this 
role. Some of the most well-characterized of these include the netrins, slits, ephrins, and 
semaphorins (1).  
 Although there is great diversity in the function and expression patterns of these 
cues, within each family they usually show strong commonalities in their protein 
structure, their effect on the direction of growing axons (attractive or repulsive), and in 
the particular corresponding families of receptors with which they interact to exert their 
effects; furthermore, cues may be secreted or membrane-bound, with some being cleaved 
from the membrane and thereby serving both roles, depending on the context (16,  15).  
 The distinctive structure that allows the axon to sense these chemical gradients in 
the surrounding environment is a highly dynamic structure known as the growth cone. 
Located at the distal end of the axon, it is marked by an elaborate infrastructure of 
microtubules and F-actin, kept in dynamic equilibrium between polymerization on one 
end and disassembly on the other, and such factors as actin rigidity and rate of retrograde 
movement (1,  14).  
 While microtubules comprise most of the core of the growth cone, at the outer 
fringes of the advancing end continually treadmilling F-actin fibers bundle together to 
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form finger-like outward projections known as filopodia, joined together around their 
bases by web-like structures, also made of F-actin, known as lamellipodia. Equipped with 
abundant receptors for the appropriate guidance cues, differing actin polymerization rates 
on opposing sides of the cone allow it to "steer" its direction of growth with great 
sensitivity, in response to the concentration gradient of guidance cues (1,  67). 
 Exactly how a guidance cue's signal is transduced after it binds its receptor--first 
across the membrane and ultimately into the form of differential changes in actin 
polymerization--remains an open question. Clues for a possible mechanism, however, 
have gradually come to light notably in research on one family of these cues, the 
semaphorins and their companion receptors, the plexins (6,  17).  
 The semaphorins are a particularly large and well-known group of mostly 
secreted, mostly repulsive axon guidance cues, whose importance also extends to blood 
vessel growth, tumor growth and chemotaxis by immune cells (20,  28,  68). They are 
distinguished by the presence of Ig-like folds and the "sema domain", a seven-bladed 
beta-propeller (15). Their dedicated receptors, the plexins, are single-pass transmembrane 
proteins with extracellular sema domains and a distinctive intracellular architecture with 
known GTPase activating (GAP) function, consisting of two intertwining (C1 and C2) 
domains of similar structure and sequence with an intervening Rho-binding (RBD) 
domain (25,  26).  
 Evidence from many studies (24,  25,  29,  30,  32,  33) indicates that the plexin 
GAP nominally exists in an autoinhibited "closed" state until binding of small GTPases 
such as Rnd1 and Rac1 to the RBD; this, combined with dimerization of the plexins 
brought about by semaphorin binding, leads to activation of the GAP function and 
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presumably several downstream effects including F-actin disassembly and growth cone 
collapse (20).  
 Perhaps the most significant of these known downstream plexin-interacting 
proteins are those of the MICAL family. The MICALs are a group of large (117 kDa), 
multi-domain proteins first recognized as an interaction partner of CasL, a large 
scaffolding protein, and vimentin (41) and later found to associate with Plexins and serve 
an important role in axon guidance in Drosophila (5,  40). MICALs are conserved from 
flies to mammals, where they are present in one and three isoforms, respectively. Perhaps 
their most distinctive biochemical feature is the presence in its N-terminal half of an 
FAD-containing domain (MO, a.a. 1-484) with strong NADPH-dependent 
monooxygenase activity and structural similarity to aromatic hydroxylases and 
monoamine oxidases (5,  69,  42).  
 In isolated form, this MO domain can generate H2O2 when NADPH and 
molecular oxygen are present (47), which may indicate a signaling role. For instance, 
MICAL-generated H2O2 may modify the oxidation state of CRMP2 (Collapsin Response 
Mediator Protein-2), thereby influencing cell contraction and growth cone collapse (58). 
However, MICAL-1 also appears to physically interact with plexins and with actin fibers 
both in vivo and in vitro (5,  51), and is capable of disassembing actin fibers directly 
through conversion of key methionines to sulfoxide, with a large concomitant increase in 
NADPH consumption (59,  65). It remains unresolved whether this function of MICAL 
involves direct enzymatic modification of actin as a substrate or is due to the production 
of very large local concentrations of H2O2, which are known to oxidize actin, and at the 
same methionine residues (70-72). However, recent reports indicate that MsrB, a 
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stereoselective sulfoxide reductase, is capable of fully restoring actin polymerization after 
MICAL treatment, indicating that MICAL itself modifies actin in a stereoselective way 
(52,  56,  60). 
 In addition to its enzymatically active MO domain, MICAL features a calponin-
homology (CH) domain (a.a. 516-617); a LIM domain (a.a. 690-752); a proline-rich 
repeat region (a.a. 822-827), known to bind preferentially bind vimentin and the CasL 
SH3 domain; a polyglutamate stretch (a.a. 856-876); and finally, a C-terminus predicted 
to be a coiled-coil/ERM-like domain (CTD; a.a. 876-1040)  (67, 44). Extensive evidence 
now supports a critical auto-inhibitory function for the MICAL CTD in controlling actin-
binding, monooxygenase activity, and actin modification (40, 51, 53). In the current 
model, it is thought that activation of the plexin intracellular domain allows it to bind to 
the MICAL CTD, uncovering the MO and actin-binding surfaces of MICAL (5, 40, 51). 
However, such activation has not been directly observed in vitro (44). 
 In this paper, we attempted to validate this model of MICAL activation and 
control by reconstituting the system using purified proteins.  
 
METHODS. 
 Genes for full-length mouse MICAL1 (fl-MICAL; a.a. 1-1048) and mouse Rnd1 
were synthesized to order by GenScript as codon optimized genes to maximize 
expression in prokaryotic hosts. Mouse Plexin A1 was obtained in plasmid form from 
American Tissue Culture. MICAL1 gene and MICAL1-MO-CH (a.a. 2-615, with Q78K 
mutation to remove a protease site) were cloned into a pET-28a vector (kanamycin 
resistance; N-terminal 6xHis tag), and Rnd1 into a pET-32a vector (ampicillin resistance; 
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THX tag with internal 6xHis). Plexin A1 intracellular domain (PlexA1ic; a.a. 1302-1912) 
and the MICAL CTD (a.a. 843-1048) were subcloned into pSmt3 (gift of Christopher D. 
Lima, Memorial Sloan-Kettering institute), a specially modified pET-28b with an N-
terminal 6xHis-SUMO tag and Ulp1 cleavage site. CasL (a.a. 2-74) was obtained from 
Genescript Inc. in codon-optimized form and cloned into a pGEX-6P2 vector, with N-
terminal GST tag. 
 Following transformation of GC5 maintenance lines, DNA purification and 
sequencing, standard BL21 expression cultures were transformed with these plasmids and 
induced with 0.6 mM IPTG. THX-Rnd1, SUMO-CTD and SUMO- PlexA1ic fusion 
proteins as well as MICAL-MO-CH expressed copiously (>6 mg/L of culture; 3 mg/L for 
MO-CH) in standard LB medium at 16 ºC for 15 hr, 210 rpm shaking. SH3 expressed at 
37 ºC in 3 hr. Owing perhaps to the large size and possible toxicity of the protein, fl-
MICAL required TB medium, 20 ºC, 15 hr, 250 rpm in a fermentor and expressed in 
much lower quantities (~0.5 mg/L).  
 All cultures were harvested by centrifuging in a GSA rotor at 5000 rpm for 25 
min, decanting and re-suspending the pellet in a small volume of 1x PBS, and either 
flash-freezing in liquid nitrogen or re-pelleting in at tabletop centrifuge at (20 minutes, 
3600 rpm in a Jouan Cr 3 22). All pellets were stored at -80 ºC until immediately before 
use. 
 Thawing was carried out in the presence of a protease inhibitor cocktail 
(Complete EDTA-free; Roche), Ca2+, Mg2+, and DNAse. Buffer conditions appropriate to 
the stability of each protein were maintained: for PlexA1ic and SUMO-CTD, 50 mM 
NaCl, 0.2 M glycine, 50 mM Tris, 5% glycerol, pH 7.3; for Rnd1, 150 mM NaCl, 50 mM 
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Tris, 5 mM MgCl2, pH 7.5; for MICAL-MO-CH, 140 mM NaCl, 50 mM Tris, pH 7.3; for 
SH3, 50 mM Tris, pH 8.0; and for fl-MICAL, 10 mM NaCl, 20mM Tris, pH 8. Pellets 
were broken by two microfluidizer passes; the resulting lysates were clarified by 
centrifugation in a (Sorvall SS-34 rotor) at 15500 rpm for 1 hour, and passed through a 
Millipore 0.22 µm (GSWP) filter.  
 Proteins were purified by FPLC by binding to a nickel IMAC affinity column (GE 
global Hitrap) and elution with 10-400 mM imidazole--except for SH3 which was 
purified by GST-Sepharose using a 0-20 mM glutathione gradient. In the case of SUMO- 
PlexA1ic, the SUMO tag was cleaved by addition of Ulp1 protease in 1:1000 mass ratio to 
the fusion protein and incubating overnight at 4 ºC. THX was cleaved by addition of 10 
units of thrombin per mg of fusion, 2.5 mM Ca2+, and incubation overnight. 6xHis was 
removed from MICAL-MO-CH and SH3 by overnight dialysis with TEV protease in 0.2 
M glycine, 50 mM Tris, pH 7.0. For simplicity, the 6xHis tag was not removed from fl-
MICAL.  
 In preparation for anion exchange, the resulting digests were desalted as necessary 
using five 5 mL GE Hitrap desalting columns in tandem (total void volume 7.5 mL). 
MICAL-MO-CH, was loaded onto a Source15S column and eluted with a 0-1 M NaCl 
gradient. Purification of CTD and Rnd1 (and removal of SUMO and THX tags) was 
achieved on a MonoQ (1 mL GL) with a 10-900 mM NaCl gradient. For SH3 and fl-
MICAL, purification using a SourceQ was found to yield better results. PlexA1ic proved 
highly pure after desalting and a second run through the IMAC to remove SUMO, 
making anion exchange unnecessary. All proteins were quantitated by absorbance at 280 
nm following denaturation in 6 M guanidine hydrochloride, based on molar absorptivity 
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coefficients calculated for the protein sequences using the Vector NTI software 
(Invitrogen, v. 10.3.0). 
 For co-precipitation experiments, rabbit muscle G-actin (Cytoskeleton, Inc.) was 
added to a concentration of 5 µM in 45 µL reaction buffer containing 1 µM fl-MICAL or 
-MO-CH and one or none of the following: Rnd1, 7 µM; PlexA1ic, 7 µM; GTP 0.5 mM. 5 
µL of 10x polymerization buffer (500 mM KCl, 20 mM MgCl2, 10 mM ATP) was added 
to initiate actin polymerization. Reactions were incubated at room temperature for 35 min, 
and ultracentrifuged at 100,000 g for 25 min. Supernatants were carefully extracted and 
mixed with Laemmli buffer, which was also used to re-suspend the pelleted fractions. 
Fractions were assessed by SDS-PAGE.  
 To test for actin-disassembling activity, after the actin polymerization step, 50 µM 
NADPH was added to the reaction mixture and incubated at room temperature 90 
minutes, followed by ultracentrifugation as above.  
 For kinetics, 11 µL of 1000 nM fl-MICAL was combined in 77 µL MICAL buffer 
with 11 µL (10 µM Rnd1 + 10 µM PlexA1ic + 1 µM Rnd1, or CTD), and 11 µL of 10x 
NADPH to give final [NADPH] of 10, 20, 50, 100 and 150 µM. The reactions were 
immediately mixed by pipetting up and down 16x and 4-minute spectrophotometric time 
courses taken, using the absorptivity at 340 nm as an indicator of NADPH concentration 
and consumption. Initial rates were plotted as a function of initial [NADPH] as an index 
of fl-MICAL activity. Reactions were run in triplicate for each NADPH concentration. 
 H2O2 concentrations were assessed using the Pierce Quantitative Peroxide Assay, 
aqueous formulation (#23280), in accordance with the manufacturer instructions. 
Standard curves were generated by measuring triplicates of absorbance at 560 nm after 
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adding known concentrations of H2O2 to each of the four main preparations: fl-MICAL 
0.1 µM; MICAL-MO-CH 0.1 µM; fl-MICAL 0.1 µM + F-actin 5.0µM; and MICAL-
MO-CH 0.1 µM + F-actin 5.0 µM. As a control, 50 µM NADPH was added to each 
preparation and the reactions immediately processed with the peroxide assay to stop the 
enzyme (the working reagent contains 25 mM H2SO4, sufficient to denature the enzyme). 
The same amount of NADPH was added and the reaction allowed to continue for 15 min. 
A340 was tracked to confirm NADPH consumption during this time, and A560 was 
immediately measured at the end for peroxide quantitation. These reactions were 
performed in triplicate. The molarities of NADPH consumed were calculated and 
compared with the molarities of H2O2 generated. 
 To confirm that plexin is dimerized under the conditions of these experiments, 
size-exclusion was carried out with 2 µM PlexA1ic in a buffer of 150 mM NaCl, 20 mM 
Tris, pH 7, using a 25 mL Superose 12 column. Fractions of the peaks were collected, 
concentrated using TCA precipitation, and assessed by SDS-PAGE gel. 
 
RESULTS. 
1. Kinetics of fl-MICAL and MICAL-MO-CH without actin and the effect of CTD in 
trans. 
 In light of the importance attributed to the CTD as an auto-inhibitory domain, 
MICAL constructs either lacking or containing this domain were tested for NADPH 
oxidation activity. A greater than ten-fold difference in activity between the full length 
MICAL construct (fl-MICAL) and one lacking the CTD (MICALMO-CH; a.a. 1-615) was 
observed (Fig. 4.1a). Furthermore, a purified construct of the MICAL CTD (a.a. 843-
 
115 
1048) proved to be a potent inhibitor of MICALMO-CH (Fig. 4.1b). 
2a. Co-sedimentation of fl-MICAL and MICALMO-CH with F-actin. 
 Previous co-sedimentation experiments suggested that the CTD, added in trans, 
may have some capacity to displace MICAL constructs lacking CTD, such as MICAL-
MO-CH, from F-actin; this in turn would support a mechanism whereby CTD controls 
actin binding by MICAL, and thereby also modification and disassembly. We 
hypothesized that fl-MICAL would be inhibited from binding F-actin in the absence of 
some other factor(s) that would displace the CTD. To test this, we expressed and purified 
fl-MICAL and carried out co-sedimentation experiments with F-actin. Surprisingly, we 
found that fl-MICAL is found entirely in the pellet after ultracentrifugation (Fig. 4.2), 
implying that it binds F-actin indistinguishably from constructs lacking the CTD. As 
controls, experiments carried out using fl-MICAL alone in the same polymerization 
buffer, but lacking actin, showed that all the protein remained in the supernatant, ruling 





Figure 4.1a. Full-length MICAL consumes NADPH approximately 10 times more 
slowly than MICALMO-CH (or other CTD-lacking MICAL constructs), indicating that 
the MICAL C-terminal region strongly inhibits the NADPH oxidase activity when 
present in cis.  
 
 
Figure 4.1b. MICALCTD, added in trans, strongly inhibits NADPH oxidase activity of 






Figure 4.2. Despite the presence of the auto-inhibitory C-terminal domain in cis, fl-
MICAL binds to F-actin similarly to constructs with the C-terminal domain removed, 




2b. F-actin fiber disassembly by fl-MICAL and MICAL-MO-CH. 
 Having observed that the CTD apparently does not preclude full-length MICAL 
from binding F-actin, we tested whether the CTD may work by inhibiting actin-
disassembly only. It has been shown that constructs of MICAL lacking the CTD can 
rapidly disassemble F-actin in the presence of NADPH (59), but this behavior has not 
been tested with the full-length protein. By simply adding an NADPH-incubation step to 
the co-sedimentation protocol, it is possible to observe dramatic disassembly of F-actin 
by MICAL-MO-CH in the presence even of quantities of the enzyme too small to appear 
on the gel (Fig. 4.3). However in the case of fl-MICAL, no disassembly is observed, even 
when the incubation time was extended several fold. These results indicate that the 
presence of the CTD, while having no effect on F-actin binding, does indeed inhibit F-
actin modification. 
2c. Kinetics of fl-MICAL and MICALMO-CH with F-actin. 
 Given the fact that fl-MICAL and MICALMO-CH can both bind to F-actin while 
exhibiting strongly different behavior regarding actin disassembly, we sought 
mechanistic clues as to the difference between the two. As expected, MICALMO-CH 
showed a dramatic increase in NADPH consumption upon addition of F-actin (Fig. 4.4). 
In contrast, in the presence of F-actin, fl-MICAL, rather than being catalytically inert, 
exhibited a dramatic increase in NADPH consumption as well, to a level similar to that 






Figure 4.3. Although fl-MICAL binds to F-actin, it shows none of the actin-
disassembling activity of other MICAL constructs lacking the C-terminus, such as 
MICALMO-CH, which even when diluted below the detection range of the gel is still 
able to disassemble a majority of the F-actin (5 µM). 
 
 
Figure 4.4. Like other MICAL constructs lacking auto-inhibition, such as MICALMO-




3. Peroxide production ratios. 
 This combination of actin binding, high NADPH consumption, and negligible F-
actin disassembly we observed for fl-MICAL in the presence of F-actin presented an 
obvious paradox: if fl-MICAL is consuming NADPH rapidly while bound to F-actin, but 
not actually disassembling actin, what are the NADPH equivalents being used for? To try 
to answer this question we measured hydrogen peroxide (H2O2) production. The Amplex 
Red is perhaps the most common method, but has been shown to be unreliable in many 
conditions (65) and, moreover, the peroxidase cross-reacts with NADPH which would 
confound the measurements. To overcome these problems we used a non-enzymatic 
assay based on the ability of peroxides to convert Fe(II) to Fe(III), which in turn reacts 
with Xanthine Orange to produce a blue adduct absorbing at 560 nm.  
 We found that in the absence of actin, despite the large difference in their overall 
activities, fl-MICAL and MICALMO-CH produced approximately as many equivalents of 
H2O2 as they consumed of NADPH (Fig. 4.5). However, in the presence of F-actin, 
MICAL-MO-CH alone showed a sharp decline in relative H2O2 production, to about 1 
H2O2 per 2 NADPH consumed. fl-MICAL, notably, showed no such decline. This result 
is consistent with the preceding findings in that it suggests fl-MICAL, though accelerated 
by binding to F-actin, remains in an essentially H2O2-producing mode; MICALMO-CH, on 
the other hand, is by itself able to couple NADPH consumption to actin modification and 
disassembly. 
4. Kinetics of fl-MICAL with Plexin/Rnd1/GTP. 





Figure 4.5. Although fl-MICAL shows an increase in the rate of NADPH consumption 
in the presence of F-actin, it shows little change in the proportion of NADPH used for 
H2O2 production. In an actin-disassembling construct such as MICALMO-CH, however, 




activation of plexins, it is expected that activation of plexin by dimerization of its 
intracellular domain and binding of an active small GTP-binding protein should convert 
plexin into an active state and activate MICAL as well. We tested this by expressing and 
purifying mouse Plexin-A1 intracellular domain (PlexA1ic) as well as mouse Rnd1. (The 
latter was chosen because it binds and is activated by, but does not hydrolyze GTP.) To 
test whether plexin is appreciably dimerized at the concentrations planned for the 
experiment, we carried out size exclusion. Indeed, approximately 20% of the total plexin 
ran in a peak adjacent to the main one, with both closely corresponding to the expected 
dimer and monomer masses, respectively: 70 and 142 kDa expected, 71.5 and 157 kDa 
from the linear fit (Fig. 4.6a). Proceeding with kinetics, we observed a substantial rate 
increase in fl-MICAL's NADPH consumption when PlexA1ic + Rnd1•GTP were added 
(Fig. 4.6b). This effect was considerably greater than that produced by a lysozyme 
control (Fig. 4.6b) 
5. Kinetics of fl-MICAL with Plexin/Rnd1•GTP and F-actin. 
 Having seen that PlexA1ic + Rnd1•GTP suffice to strongly enhance fl-MICAL 
activity, and that fl-MICAL by itself is unable to disassemble F-actin, we expected that 
these proteins might indeed be the key to activating the F-actin disassembly mechanism. 
However, kinetic measurements showed that addition of PlexA1ic + Rnd1•GTP resulted 
in no further increase in the rate of NADPH consumption by fl-MICAL over that already 
seen from F-actin alone (Fig. 4.7a). Furthermore, co-sedimentation showed no change in 
F-actin binding or disassembly by fl-MICAL in the presence of these factors (Fig. 4.7b). 





Figure 4.6a. Under conditions similar to the kinetics experiments, PlexA1ic shows a 
significant shoulder peak, which elutes from size exclusion at a volume very closely 
corresponding to a dimer (~150 kDa). 
 
 
Figure 4.6b. The combination of PlexA1ic and Rnd1*GTP nearly triples the NADPH 
consumption of fl-MICAL, while PlexA1ic alone shows a weaker effect. Lysozyme, as 






Figure 4.7a. In the presence of F-actin, PlexA1ic and Rnd1*GTP produce no additional 
acceleration of fl-MICAL NADPH consumption. 
 
 
Figure 4.7b. Co-sedimentation reveals that PlexA1ic with Rnd1*GTP also does not 
affect actin binding by fl-MICAL, nor does it activate F-actin disassembly. MICALMO-





Figure 4.8. The SH3 domain of CasL does not activate fl-MICAL NADPH oxidation in 
the presence of F-actin and in fact strongly inhibits it, arguing against CasL being the 





disassembly by fl-MICAL. 
6. Kinetics of fl-MICAL with CasL SH3 and F-actin. 
 Due to the known interaction of CasL's SH3 domain with fl-MICAL, it was a 
plausible candidate for activating F-actin disassembly by fl-MICAL. Therefore, we tested 
whether adding SH3 of CasL might increase NADPH oxidation by fl-MICAL in the 




 Our experiments have focused on the current model of MICAL activation and 
control in an attempt to identify the main factors involved in MICAL activation and 
reconstitute the expected properties of the system. The association of MICAL's CTD with 
the plexin intracellular domain, and the CTD's ability to function, in turn, as a dominant 
negative suppressor of MICAL (5), is directly connected with the model of Plexin 
activation outlined, for example, in the work of Negishi & Katoh (24,  33,  20,  73). The 
latter studies relied on cell-based studies in COS-7 cells to show that dimerization or 
clustering with anti-plexin antibodies was necessary for semaphorin signal transduction. 
Earlier work has outlined the association of GTP-bound Rnd1 with Plexin and its role in 
actin disassembly (34,  35,  64). Based on structural results, such as the location of the 
Rho-binding domain and the known propensity of plexins to form at least 
crystallographic dimers, the activation of plexin has been described as an "AND-gate" 
(25), requiring concommitant binding of GTP-bound Rnd1 (or Rac1) and clustering. 
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 Our results confirm some aspects of this model of MICAL activation, but in many 
respects diverge greatly from it. While we were able to detect a considerable increase in 
the NADPH oxidation kinetics of fl-MICAL in the presence of Plexin and Rnd1•GTP 
(greater than control), we did not detect any such enhancement for actin-bound fl-
MICAL (indeed if anything there was a slight slowdown). Furthermore, these two 
proteins exhibited no ability to induce F-actin disassembly by fl-MICAL. Since CasL 
SH3 domain is another well-known interactor of MICAL (41) it seemed a plausible 
alternate candidate for the activator, but it actually inhibited fl-MICAL strongly in the 
presence of F-actin.  
 Transfection of the CTD has been reported to function as a dominant-negative (5) 
and halt MICAL H2O2 production (as measured by Amplex Red) and its deletion from the 
MICAL gene gives phenotypes resembling constitutive semaphorin signaling (40,  51,  
53). Consistent with the expectation that the presence of the CTD results in auto-
inhibition, we have observed that that full-length MICAL consumes NADPH far more 
slowly than a construct lacking the CTD region; also, the last ~205 residues of the CTD 
appears able in trans to restore this auto-inhibition, strongly inhibiting NADPH 
consumption of the MICAL-MO-CH variant (Ki=~300 nM). However, we found the 
presence of the CTD in cis to have little or no effect on the actual actin-binding property 
of fl-MICAL versus MICAL-MO-CH. Co-sedimentation experiments suggest that large 
molar excess of CTD in trans (>5x) can weakly displace MICAL-MO-CH and -MO 
(Kd=~5 µM) from F-actin, but it does not appear to make any major difference in the case 
of full-length MICAL (with a CTD to MICAL ratio of 1:1).  
 A more complex role for the CTD is also suggested by the enzymatic behavior of 
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fl-MICAL in the presence of F-actin. Whereas we expected (based on the simple need to 
keep potentially toxic H2O2 production tightly regulated) that the CTD would continue to 
restrain NADPH consumption to at most the level of a leak until its displacement by 
some specific activating factors (Plexin + Rnd1•GTP), we instead find that F-actin alone 
is sufficient to increase fl-MICAL NADPH consumption to something on the order of the 
non-autoinhibited MICAL-MO-CH. Yet, both the absence of any observable disassembly 
of F-actin and the lack of any stoichiometric deficit of H2O2 production by F-actin bound 
fl-MICAL suggests a distinct mechanism from that involved in actin disassembly is at 
work in this case. 
 In view of these results it appears that, in the absence of other factors, the CTD of 
fl-MICAL is displaced or adjusted upon actin binding in such a way as to allow increased 
access of O2/NADPH to the active site, but not significant access or modification of the 
two proposed substrate actin residues (M44 and M47). The CTD may therefore function 
as a "flap" that can be variably displaced, leading to different modes of operation. 
Structural determination of the CTD would undoubtedly assist in resolving this question, 
but its extremely high solubility and tendency to misfold has impeded crystallization 
attempts thus far. 
 Overall, a key outstanding issue is to determine exactly what additional factor(s) 
are necessary to switch fl-MICAL into the actin-disassembling state that is so readily 
observed in constructs lacking the CTD, and which is evinced by numerous cell-based 
and in vitro studies (40,  51-53,  59,  60,  55). This factor may work in concert with 
plexin and Rnd1, perhaps being itself activated to carry out the MICAL actin-
disassembly function. Certainly more proteins can be purified and tested in the reaction 
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mixture, in the manner of a screen, but the lack of compelling candidate(s) at the moment, 
the difficulties of expressing many of these proteins in large amounts, as well as the 
growing complexity of possible cross-reactions as more proteins are added limits this 
approach. Possibly further genetic, cell-based or interaction studies will turn up more 
leads which could then be tested in this system. 
 One possibility that is consistent with our findings, however, is that Plexin and 
Rnd1 do not directly control MICAL's actin disassembly function, but rather exert their 
effects on axon guidance by first modulating its H2O2-production. Prior to the discovery 
of its actin-modifying capability, fl-MICAL was proposed to operate as a signaling 
protein, using the small molecule H2O2, (40,  44,  42,  58,  69). There is no question at 
this point that H2O2 can act as a signaling molecule, with significant effects on actin's 
redox state (48-50,  69). Indeed, other observations of MICAL kinetics have suggested 
that it may exhibit multiple phases of activity or dual roles in actin disassembly, or even 
that in some cases its actin disassembly may be spontaneously reversible (43,  44,  65).  
 Furthermore, free-floating Plexin intracellular domain in isolation is never found 
in normal axon guidance; it is always connected directly to the Plexin transmembrane 
helix. Therefore if direct physical interaction between plexin and MICAL is necessary for 
MICAL activity, and at the same time direct interaction between MICAL and F-actin is 
required for disassembly, it should only be possible for MICAL to disassemble actin that 
is extremely close to the membrane, leaving the vast majority of the F-actin in the growth 
cone (and cell) inaccessible.  
 Growth-cone dynamics is thought to involve actin "treadmilling", with assembly 
taking place at the distal (membrane) edge, and disassembly generally occurring 
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proximally, deeper in the cytosol (1). Therefore, MICAL would have to modify a 
significant amount of actin either before or the instant it polymerized, before it diffused 
or treadmilled out of reach of the MICAL-plexin complex. It is unclear whether this 
occurs or is possible.  
 On the other hand, it does seem clear that large quantities of MICALs localize to 
the cytosol, well out of reach of plexin, yet can and do disassemble actin there. Further, in 
MICAL-overexpressing cells, F-actin often is depleted in the cytosol and enriched near 
the membrane (59,  53). This cannot be accounted for by direct activation by a 
membrane-bound plexin, but again suggests an additional factor is required for F-actin 
disassembly, possibly involving a peroxide signal. 
 It seems plausible, then, that H2O2 signaling (or some other messenger produced 
by activated MICAL at the membrane) activates another population of MICAL molecules 
located deeper within the cytosol, allowing for actin disassembly there. Our observation 
of distinct modes of operation for the same molecule, with very different levels of H2O2 
production versus actin modification activity and highly differing responses depending on 
F-actin occupancy, suggests that the proposal of H2O2 signaling may remain integral to 
some aspects of MICAL function. An important challenge for future work will involve 
isolating these aspects, for example by searching for mutants or inhibitors that produce 




Chapter 5: Conclusions and Future Directions. 
 5.1. Conclusions and ongoing questions.  
 The present results potentially point the way to a more nuanced understanding of 
MICAL activation, by hinting that the peroxide-producing and actin-disassembling 
reaction of the enzyme might serve distinct functions, and be carried out by spatially 
distinct sub-populations of the total MICAL population of the cell.  
 5.2. Finding the "reservoir" of inactive MICAL. 
 Given the relatively high H2O2 production of free fl-MICAL when it finds F-actin, 
and the likely physiological harm of such if not regulated, it is plausible that some kind of 
additional sequestering or inactivating principle is at work in keeping this binding in 
check most of the time. A natural possibility, given its strong inhibitory effect on MICAL 
NADPH oxidase activity, is CasL. It is already known of course that MICAL interacts 
with the SH3 domain of CasL, but those same experiments also found an equal if not 
stronger co-localization of MICAL with vimentin (41). 
Further experiments should be carried out to assess the role of the intermediate 
filaments as a "reservoir" of cellular MICAL, with CasL, for example with peroxide-
sensitive fluorophores conjugated with vimentin-binding antibodies. In general, in 
keeping with the model of separate functions, little peroxide should be detectable from 
MICAL deeper in the cell, while larger amounts should appear near the membrane; the 
reverse pattern should be evident if actin-disassembly is monitored, for example by 
pyrene-labeling of a fraction of the cellular actin.  
Crucially, such peroxide production and actin disassembly must also be seen to 
change in a time-dependent way if it is to be deemed consistent with not just a steady-
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state balancing out of MICAL effects, but with signaling: information transmission by 
external guidance stimuli, e.g., by a causal dependence on addition of semaphorin signal 
to the extracellular medium.  
For example, although recent results (52) have shown that MsrB expression can 
rescue the phenotypic effects of MICAL overexpression or constitutive activity and that it 
produces such effects when underexpressed, the importance of MsrB in actually carrying 
an actin de-oxidizing “signal”--rather than, say, in merely establishing a steady-state 
cellular redox set-point through a kind of “oxidative tug-of-war” with MICAL, is unclear.  
Indeed, given that mice null for both Msr enzymes survive to adulthood and do 
not show serious neurological problems (61), the shallow active sites and low substrate 
specificity of the Msr enzymes (74), and the fact that many of the rescues demonstrated 
by MsrB overexpression are actually against MICALMO-CH--a construct that, being 
constitutively active, is inherently incapable of signaling (52)—the role of Msr and even 
of MICAL’s actin-disassembly function in a semaphorin-signaling context remain to be 
clarified. 
 5.3. Assessing causes for inability of fl-MICAL to modify F-actin.  
 Another question that arises from these results is that, if MICAL modifies actin by 
making locally high [H2O2], not by direct substrate modification, how could that local 
concentration not be enough to modify M44/47 in the case of fl-MICAL, but plenty high 
for MICAL-MOCH when both are sitting right on the actin? Two possible explanations 
that come to mind. First, that there is an enzymatic activity that disassembles F-actin but 
is not turned when the CTD is still present in cis with no other factors; or, second, that the 
CTD of fl-MICAL obscures M44/47 in such a way that little or no peroxide is able to 
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reach and modify these residues. To test these possibilities, NMR could be employed to 
measure deuterium exchange with the solvent, thus probing the solvent exposure of actin 
M44/47 when different MICAL constructs are bound and particularly in the presence or 
absence of CTD in cis. 
 5.4. Parsing of plexin downstream signaling. 
 In addition to the "AND-gate model" requiring two different and simultaneous 
inputs in order to be activated, plexin in turn acts upon actin polymerization through at 
least two essential routes: through MICAL activation by the plexin C2 domain upon 
receptor activation, and through down-regulation of R-Ras and M-Ras signaling mediated 
by the GTPase-activating protein (GAP) function of plexin (24,  25). Plexin activates Rho 
and Rac, these activate LIMK1, which then phosphorylates cofilin, which then becomes 
inactive (37). 
 Prior work (29) has suggested that cell collapse through plexin signaling requires 
the latter's GAP activity, and particularly the two conserved catalytic arginines, R1407 
and 1724 (24,  25). Therefore it would be interesting to test whether MICAL--which is 
very unlikely to be a substrate of a GTPase-activating domain such as plexin's--
nonetheless requires intact plexin GAP activity in order to bridge plexin activation and 
actin depolymerization.  
 "Inactive" mutants of plexin's GAP--particularly of the C2 arginine R1724--could 
be prepared and tested for effects on fl-MICAL enzymatic activity using many of the in 
vitro reconstitution methods described in the foregoing, while binding between the C2 
domain and MICAL could be probed by co-immunoprecipitation and MALDI-TOF. 
However, possibly the most likely finding will be that Ras-GAP activity and MICAL 
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activation serve complementary, rather than overlapping roles. It might also be of interest 
to experiment on the effects of R-Ras as opposed to MICAL mutations on cell 
contraction, for instance in COS-7 cells. 
 5.5. Structural determination of MICAL-CTD.  
 There remains a sore need for structural study to shed light on the mechanistic 
side of these observations. Structures of intracellular plexin A and B domains were 
solved as early as 2007, and given the very high degree of sequence similarity among the 
plexin A intracellular regions, it is likely that not much new would be contributed by a 
structure of Plexin A1, say, versus Plexin A3 which has >80% identity and serves a 
closely similar function.  
 Similarly, structures have long since been reported for Rnd1 itself, as well as 
bound to the Plexin rho-binding domain (34), although a co-crystal of the full plexin 
intracellular domain bound to GTP-bound Rnd1 might provide useful insight into the 
intramolecular changes that underlie plexin activation. This was not attempted in any of 
the crystallization trials here described and would be an important challenge, especially 
in consideration of the kinetics results showing that plexin intracellular domain combined 
with GTP-bound Rnd1 are able to significantly accelerate fl-MICAL NADPH 
consumption and H2O2 production.  
 Probably the most directly useful structural result, which is still lacking, would be 
resolution of the MICAL C-terminal region. Co-crystallization attempts of this with the 
MICAL-MO domain may have been unsuccessful using known MICALMO crystallization 
conditions, but this task merits further work. The structure of the C-terminus alone could 
also reveal a great deal about how MICAL is regulated, including its paradoxical restraint 
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of H2O2 production and simultaneous easy displacement to allow F-actin binding.  
 5.6. Studies of MICAL-CTD oligomerization. 
 There remains the matter, implied in the HPLC and size-exclusion results, of the 
CTD’s tendency to oligomerize even before misfolding per se. Different solution 
conditions, or mutagenesis as above but with the aim of reducing intermolecular 
interactions, might hold the key. Also it is not understood whether such oligomerization 
might somehow be a feature of the CTD’s normal operation, so future experiments 




Appendix: Cloning, Expression, Purification and Crystallization Attempts on HIF-
2α and Respiratory Syncytial Viral Proteins M2-1 and P. 
 A.1. Introduction to Hypoxia-Inducible Factor 2-alpha (HIF2α). 
 Hypoxia-inducible factors (HIF-1 and -2) are heterodimeric proteins, comprised 
of HIF-1β (ARNT) and either HIFα (1α or 2α), that couple cellular oxygen levels to gene 
expression in metazoa (75). The main mechanism for their achieving this depends on 
three main features: 1) constitutive expression of both HIF monomers; 2) a strongly 
oxygen-dependent prolyl hydroxylase activity, which marks key prolines of HIF-1α and 
2α for E3 ubiquitin ligase-mediated degradation; and 3) the transcription factor activity 
of the HIF heterodimers, which stimulates expression of hundreds of target genes through 
binding to Hypoxia Response Elements in DNA (HREs)  (76).  
 By this arrangement, decreases in oxygen levels lead to decreased degradation of 
the HIF-1/2α monomers and increased levels of the HIF transcription factor and of HRE-
controlled genes. Such genes include VEGF, GLUT1, Semaphorin 4D, hexokinase, and 
histone demethylases (76,  77,  78). 
 Each HIF monomer contains an N-terminal basic helix-loop-helix (bHLH) 
domain, responsible for DNA-binding, a Per-ARNT-Sim (PAS-B) domain, which is 
thought to be primarily responsible for dimerization, and C-terminal sequences that 
recruit transcriptional coactivators (75,  79). Structural studies have found that PAS-B 
domains in general are capable of extraordinary conformational flexibility in response to 
mild perturbations, and surprisingly, the PAS-B domain of HIF-2α contains a large cavity 
(~290 Å3) capable of holding a variety of small molecule ligands (75,  80). 
 One such candidate is the small molecule acriflavine (Fig. A1), which was 
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discovered through a cell-based library screen to block formation of the HIF-1 
heterodimer. It does so by binding to the normal heterodimerization region on HIF-1α 
(76). Moreover, acriflavine demonstrated an ability to reduce or halt tumor progression in 
a mouse prostate cancer model (76). Given these observations--as well as the highly pro-
proliferative, pro-angiogenic, pro-glycolytic, and anti-silencing nature of most HIF 
transcription target genes, the need for cancer cells to adapt to the often hypoxic tumor 
environment, and the fact that high expression of HIF in tumors corresponds to poorer 
clinical outcomes (76,  81)--blocking HIF dimerization presents a promising target for 
cancer therapy. We therefore sought to determine the structure of the HIF-2α PAS-B 
domain co-crystallized with acriflavine. 
 A.1.1. Experiments with HIF2α. 
HIF-2α (PAS-B region, a.a. 281-410) was initially obtained already cloned into a 
PGEX-5X vector (courtesy of Dr. Greg Semenza, Johns Hopkins School of Medicine). 
This construct produces fusion protein containing a GST tag, which is removable by 
Factor Xa, which cleaves at I(E/D)GR sequence sites. Although it expressed readily (up 
to 20 mg/L of fusion in LB) in most constructs tried, and Factor Xa cleavage and GST tag 
removal proceeded well (>95% cleavage after 8 hr, using 1 U per µM fusion, in 20 mM 
Tris, 100 mM NaCl, 2 mM CaCl2, pH 8 (Fig090415), followed by protease inactivation 
with PMSF or removal with Factor Xa beads, the PAS-B domain of HIF-2α was highly 
prone to precipitation after tag removal, with frequently more than two-thirds of the 
original sample precipitating during purification.  
Other attempts to remove the GST tag, such as through a MonoS column, also 
resulted in dramatic losses of protein (more than 6/7 of the total), suggesting that the 
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presence of GST even after cleavage was necessary to some degree for stabilization. Part 
of the overall problem as well had to do with the tendency of HIF-2α to precipitate in the 
presence of calcium--which is however required for Factor Xa cleavage.  
 In an attempt to overcome these problems, a variety of buffer and expression 
conditions were tested. After initial test expression runs of 3 hours at 37 ºC, induction 
temperature was decreased to 25º, then 18º, for periods ranging from 6 hours to overnight 
(~12 hours), with IPTG amounts between 0.4 and 1.0 mM and optical densities at 
induction between 0.6 and 1.5. Gels from the pellet following these inductions were 
generally uninformative, as the yield of protein was very high in all cases and seemed to 
have no bearing on the instability of the molecule. 
SourceQ separation was more successful at separating HIF-2α from GST, 
yielding up to 1.5 mg/mL (Fig. A2). However, concentrations higher than 5 mg/mL were 
not achieved, as the HIF-2α would jam the concentrator. Crystallization trays were 
attempted using the conditions reported for the HIF heterodimer in Scheuermann et al. 
(75): 100 mM BisTris, 15-30% PEG 3350, and pH 5.5-6.5. This and similar conditions 
did not produce crystals for the monomer. Hampton Cryo HT and Crystal Screen did not 
produce leads. 
 Given the success experienced previously with Plexin A1 intracellular domain, a 
SUMO-containing construct of HIF-2α was prepared, but this exhibited many of the 
same basic problems: reasonable amounts of fusion could be obtained, and concentrated, 
but upon removal of the SUMO tag solubility plummeted. Best solubilities were attained 





Figure A1. Structure of acriflavine (acriflavinium chloride), a dye commonly used as 
an antiseptic. Acriflavine has been observed to retard tumor growth, most likely by 
interfering with HIF dimerization. 
 
Figure A2. Typical elution, cleavage and SourceQ purification of GST-HIF2α PAS-B 
fusion. Factor Xa cleavage of the GST tag is nearly complete by 4.5 hours, and PAS-B 




of acriflavine itself (50 µM) did not seem to improve the chances of crystallization, nor 
the stability of the protein in solution.  
 A.2 Introduction to Respiratory Syncytial Virus Proteins M2-1 and P. 
 Respiratory syncytial virus (RSV), of the pneumovirus family, is a common cause 
of bronchiolitis in infants, affecting nearly 100% within the first 2 years of life (82). Also, 
the bovine form of the disease, BRSV, causes widespread infections of calves, leading to 
major economic losses for the cattle industry (83). 
 M2-1 and P are two interacting components of the RSV transcriptional machinery, 
concentrating at cytoplasmic inclusion bodies where viral RNA is synthesized. M2-1, 
which forms a tetramer, functions as an RNA-binding processivity factor (82), while P is 
a competitive inhibitor of RNA binding to M2-1. Interestingly, NMR studies indicate 
M2-1 bears structural homology to the Ebola virus VP30 protein (83). 
 Mutants in the P-interaction region of M2-1, or in the regions responsible for 
tetramer formation, show reduced RNA transcription (82), indicating that such 
interactions are a potential target for antiviral drugs (in much the same manner that 
acriflavine is for HIF in cancers). We therefore sought crystal structures of both M2-1 
and P separately, and potentially in dimerized form. 
 A.2.1 Reconstitution and crystallization of M2-1 and P. 
 Respiratory syncytial virus proteins M2-1 and P were expressed, purified and sent 
in lyophilized form from the laboratory of Dr. G. Pratt-Gay, Inst. Beloir. Upon arrival 
they were reconstituted with pure water with 20 mM DTT, then dialyzed overnight into a 
buffer of 50 mM phosphate buffer, pH 7, with 0.4 M NaCl, 1 mM DTT, and 40 µM 
ZnSO4. Thereafter the samples were centrifuged and concentrated until M2-1 reached 3.2 
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mg/mL and P reached 2.10 mg/mL, then frozen at -80 ºC with 15% glycerol.  
 Crystal trays were then prepared, including Hampton Crystal Screen HT, 
Hampton Cryo, and Nextal PEGs suite and a screen designed using the Formulatrix 
software, based on common ingredients of promising drops found from the PEGs suite. 
In the case of P protein, this process led to improved conditions, and trays were set up 
using 20 mM HEPES, pH 7.0-8.0 and Li2SO4 1.2-1.7 M. These produced large amounts 
of crystals, and in subsequent trays the pH range was increased to 7.8-8.8 while the 
Li2SO4 was reduced to between 0.8 and 1.3 M. Crystals produced by this method 
appeared to be twinned however, with a distinct cruciform shape being apparent at the 
edges of the crystallization condition (Fig. A3). Crystals closer to the center of the 
conditions range were irregular in shape, possibly radiations of tiny separate crystals 
outward from a central point.  
 One such crystal produced an unmistakable protein diffraction pattern, to about 8 
Å (Fig. A4). But, though more crystals were produced by these and similar conditions 
and mounted and shot, no further protein diffraction was observed, other than salt. Later 
M2-1 also produced similar irregular, probably compound "crystals"; none produced 





Figure A3. Example of crystals obtained from respiratory syncytial virus protein P. 
Note the distinctive bi-lobed crystal habit, which with varying conditions becomes 
cruciform or irregular. 
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